

NY2 - 1130121.1

PENNIE & EDMONDS LLP
 COUNSELLORS AT LAW
 1155 Avenue of the Americas
 New York, N.Y. 10036-2711
 (212) 790-9090

ATTORNEY DOCKET NO. 7991-086Date: October 10, 2000

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Beetham et al.

Executed on: unexecuted

Title of Invention: NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	38	-20	18	\$18.00 each	\$ 324.00
Independent	5	-3	2	\$80.00 each	\$ 160.00
Minimum Fee					\$ 710.00
Multiple Dependency Fee If Applicable (\$270.00)					\$ 270.00
Total					\$ 1,464.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					- \$ 0.00
Total Filing Fee					\$ 1,464.00

☒ This application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and U.S. Provisional Application No. 60/173,564, filed December 30, 1999.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Thomas E. Friebel
 Thomas E. Friebel
 PENNIE & EDMONDS LLP
 (Reg. No.) 29,258

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

NON-TRANSGENIC HERBICIDE
RESISTANT PLANTS

TABLE OF CONTENTS

5	1.	FIELD OF THE INVENTION	1
	2.	BACKGROUND TO THE INVENTION	1
	2.1	PHOSPHONOMETHYLGLYCINE HERBICIDES	1
10	2.2	RECOMBINAGENIC OLIGONUCLEOBASES	3
	3.	SUMMARY OF THE INVENTION	4
	3.1	DEFINITIONS	5
15	4.	BRIEF DESCRIPTION OF THE FIGURES	7
	5.	DETAILED DESCRIPTION OF THE INVENTION	8
	5.1	RECOMBINAGENIC OLIGONUCLEOBASES	9
	5.2	THE LOCATION AND TYPE OF MUTATION INTRODUCED INTO THE EPSPS GENE	14
20	5.3	THE DELIVERY OF RECOMBINAGENIC OLIGONUCLEOBASES INTO PLANT CELLS	18
	5.3.1	MICROCARRIERS AND MICROFIBERS	18
	5.3.2	PROTOPLAST ELECTROPORATION	19
	5.3.3	WHISKERS AND MICROINJECTION	20
25	5.4	SELECTION OF GLYPHOSATE RESISTANT PLANTS	20
	6.	EXAMPLE	20
	6.1	MATERIAL AND METHODS	20
30	6.1.1	ISOLATION OF <i>ARABIDOPSIS THALIANA</i> EPSPS cDNA	20
	6.1.2	PREPARATION OF THE EXPRESSION VECTOR	21
	6.1.3	CLONING OF THE ARABIDOPSIS EPSPS GENE INTO BACTERIAL EXPRESSION VECTOR	21
35	6.1.4	NOVEL POINT MUTATIONS IN THE EPSPS GENE	21
	6.1.5	GLYPHOSATE RESISTANCE ASSAYS	22

	6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES	22
5	6.2 RESULTS	23
	WE CLAIM:	24
10	ABSTRACT	29

15

20

25

30

35

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

The present application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and to U.S. Provisional Application No. 60/173,564, filed December 30, 1999, the disclosures of each of which are incorporated by reference herein in their entirety.

1. FIELD OF THE INVENTION

The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, *e.g.*, glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. The present invention also relates to a non-transgenic plant cell in which the EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a plant resulting from a cross using a regenerated non-transgenic plant having a mutated EPSPS gene.

2. BACKGROUND TO THE INVENTION

2.1 PHOSPHONOMETHYLGLYCINE HERBICIDES

Herbicide-tolerant plants may reduce the need for tillage to control weeds thereby effectively reducing soil erosion. One herbicide which is the subject of much investigation in this regard is N-phosphonomethylglycine, commonly referred to as glyphosate. Glyphosate inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, hormones and vitamins. Specifically, glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter referred to as EPSP synthase or EPSPS). For purposes of the present invention, the term "glyphosate" includes any herbicidally effective form of N-phosphonomethylglycine (including any salt thereof), other forms which result in the production of the glyphosate anion in plants and any other herbicides of the phosphonomethylglycine family.

5 Tolerance of plants to glyphosate can be increased by introducing a mutant EPSPS gene having an alteration in the EPSPS amino acid coding sequence into the genome of the plant. Examples of some of the mutations in the EPSPS gene for inducing glyphosate tolerance are described in the following patents: U.S. Patent No. 5,310,667; U.S. Patent No. 5,866,775; U.S. Patent No. 5,312,910; U.S. Patent No. 5,145,783. These proposed mutations typically have a higher K_i for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate-tolerant phenotype, but these variants are also characterized by a high K_m for PEP which makes the enzyme kinetically less efficient (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663; Schulz et al., 1984, Arch. Microbiol. 137: 121-123; Sost et al., 1984, FEBS Lett. 173: 238-241; Kishore et al., 1986, Fed. Proc. 45: 1506; Sost and Amrhein, 1990, Arch. Biochem. Biophys. 282: 433-436). Many mutations of the EPSPS gene are chosen so as to produce an EPSPS enzyme that is resistant to herbicides, but unfortunately, the EPSPS enzyme produced by the mutated EPSPS gene has a significantly lower enzymatic activity than the wild-type EPSPS. For example, the apparent K_m for PEP and the apparent K_i for glyphosate for the wild-type EPSPS from *E. coli* are 10 μ M and 0.5 μ M, while for a glyphosate-tolerant isolate having a single amino acid substitution of alanine for glycine at position 96, these values are 220 μ M and 4.0 mM, respectively. A number of glyphosate-tolerant EPSPS genes have been constructed by mutagenesis. Again, the glyphosate-tolerant EPSPS had lower catalytic efficiency (V_{max}/K_m), as shown by an increase in the K_m for PEP, and a slight reduction of the V_{max} of the wild-type plant enzyme (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

Since the kinetic constants of the variant enzymes are impaired with respect to PEP, it has been proposed that high levels of overproduction of the variant enzyme, 40-80 fold, would be required to maintain normal catalytic activity in plants in the presence of glyphosate (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663). It has been shown that glyphosate-tolerant plants can be produced by inserting into the genome of the plant the capacity to produce a higher level of EPSP synthase in the chloroplast of the cell (Shah et al., 1986, Science 233, 478-481), which enzyme is preferably glyphosate-tolerant (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

The introduction of the exogenous mutant EPSPS genes into plant is well documented. For example, according to U.S. Patent No. 4,545,060, to increase a plant's resistance to glyphosate, a gene coding for an EPSPS variant having at least one mutation that renders the enzyme more resistant to its competitive inhibitor, *i.e.*, glyphosate, is introduced into the plant genome. However, many complications and problems are associated with these examples. Many such mutations result in low expression of the mutated EPSPS gene product or result in an EPSPS gene product with significantly lower

enzymatic activity as compared to wild type. The low expression or low enzymatic activity of the mutated enzyme results in abnormally low levels of growth and development of the plant.

While such variants in the EPSP synthases have proved useful in obtaining transgenic plants tolerant to glyphosate, it would be increasingly beneficial to obtain a variant EPSPS gene product that is highly glyphosate-tolerant but still kinetically efficient, such that improved tolerance can be obtained with a wild-type expression level.

2.2 RECOMBINAGENIC OLIGONUCLEOBASES

Recombinagenic oligonucleobases and their use to effect genetic changes in eukaryotic cells are described in United States patent No. 5,565,350 to Kmiec (Kmiec I). Kmiec I teaches a method for introducing specific genetic alterations into a target gene. Kmiec I discloses, *inter alia*, recombinagenic oligonucleobases having two strands, in which a first strand contains two segments of at least 8 RNA-like nucleotides that are separated by a third segment of from 4 to about 50 DNA-like nucleotides, termed an “interposed DNA segment.” The nucleotides of the first strand are base paired to DNA-like nucleotides of a second strand. The first and second strands are additionally linked by a segment of single stranded nucleotides so that the first and second strands are parts of a single oligonucleotide chain. Kmiec I further teaches a method for introducing specific genetic alterations into a target gene. According to Kmiec I, the sequences of the RNA segments are selected to be homologous, *i.e.*, identical, to the sequence of a first and a second fragment of the target gene. The sequence of the interposed DNA segment is homologous with the sequence of the target gene between the first and second fragment except for a region of difference, termed the “heterologous region.” The heterologous region can effect an insertion or deletion, or can contain one or more bases that are mismatched with the sequence of target gene so as to effect a substitution. According to Kmiec I, the sequence of the target gene is altered as directed by the heterologous region, such that the target gene becomes homologous with the sequence of the recombinagenic oligonucleobase. Kmiec I specifically teaches that ribose and 2'-O-methylribose, *i.e.*, 2'-methoxyribose, containing nucleotides can be used in recombinagenic oligonucleobases and that naturally-occurring deoxyribose-containing nucleotides can be used as DNA-like nucleotides.

U.S. Patent No. 5,731,181 to Kmiec (Kmiec II) specifically disclose the use of recombinagenic oligonucleobases to effect genetic changes in plant cells and discloses further examples of analogs and derivatives of RNA-like and DNA-like nucleotides that can be used to effect genetic changes in specific target genes. Other patents discussing the use

of recombinagenic oligonucleobases include: U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

- 5 Recombinagenic oligonucleobases include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in Kmiec II and other molecules taught in the above-noted patents and patent publications.

Citation or identification of any reference in Section 2, or any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having one or more mutations in the EPSPS gene, which plant has increased resistance or tolerance to a member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety by reference herein:

30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or gymnospermous plant, including any woody plant species that grows as a tree or shrub, any herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds, the method comprising application to the field of a herbicide to which the said plants have been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

3.1 DEFINITIONS

The invention is to be understood in accordance with the following definitions.

An oligonucleobase is a polymer of nucleobases, which polymer can hybridize by Watson-Crick base pairing to a DNA having the complementary sequence.

Nucleobases comprise a base, which is a purine, pyrimidine, or a derivative or analog thereof. Nucleobases include peptide nucleobases, the subunits of peptide nucleic acids, and morpholine nucleobases as well as nucleosides and nucleotides. Nucleosides are nucleobases that contain a pentosefuranosyl moiety, *e.g.*, an optionally substituted riboside or 2'-deoxyriboside. Nucleosides can be linked by one of several linkage moieties, which may or may not contain a phosphorus. Nucleosides that are linked by unsubstituted phosphodiester linkages are termed nucleotides.

An oligonucleobase chain has a single 5' and 3' terminus, which are the ultimate nucleobases of the polymer. A particular oligonucleobase chain can contain

nucleobases of all types. An oligonucleobase compound is a compound comprising one or more oligonucleobase chains that are complementary and hybridized by Watson-Crick base pairing. Nucleobases are either deoxyribo-type or ribo-type. Ribo-type nucleobases are pentosefuranosyl containing nucleobases wherein the 2' carbon is a methylene substituted with a hydroxyl, alkyloxy or halogen. Deoxyribo-type nucleobases are nucleobases other than ribo-type nucleobases and include all nucleobases that do not contain a pentosefuranosyl moiety.

An oligonucleobase strand generically includes both oligonucleobase chains and segments or regions of oligonucleobase chains. An oligonucleobase strand has a 3' end and a 5' end. When a oligonucleobase strand is coextensive with a chain, the 3' and 5' ends of the strand are also 3' and 5' termini of the chain.

According to the present invention, substantially normal growth of a plant, plant organ, plant tissue or plant cell is defined as a growth rate or rate of cell division of the plant, plant organ, plant tissue, or plant cell that is at least 35%, at least 50%, at least 60%, or at least 75% of the growth rate or rate of cell division in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention, substantially normal development of a plant, plant organ, plant tissue or plant cell is defined as the occurrence of one or more developmental events in the plant, plant organ, plant tissue or plant cell that are substantially the same as those occurring in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention plant organs include, but are not limited to, leaves, stems, roots, vegetative buds, floral buds, meristems, embryos, cotyledons, endosperm, sepals, petals, pistils, carpels, stamens, anthers, microspores, pollen, pollen tubes, ovules, ovaries and fruits, or sections, slices or discs taken therefrom. Plant tissues include, but are not limited to, callus tissues, ground tissues, vascular tissues, storage tissues, meristematic tissues, leaf tissues, shoot tissues, root tissues, gall tissues, plant tumor tissues, and reproductive tissues. Plant cells include, but are not limited to, isolated cells with cell walls, variously sized aggregates thereof, and protoplasts.

Plants are substantially "tolerant" to glyphosate when they are subjected to it and provide a dose/response curve which is shifted to the right when compared with that provided by similarly subjected non-tolerant like plant. Such dose/response curves have "dose" plotted on the X-axis and "percentage kill", "herbicidal effect", etc., plotted on the y-axis. Tolerant plants will require more herbicide than non-tolerant like plants in order to produce a given herbicidal effect. Plants which are substantially "resistant" to the glyphosate exhibit few, if any, necrotic, lytic, chlorotic or other lesions, when subjected to

glyphosate at concentrations and rates which are typically employed by the agrochemical community to kill weeds in the field. Plants which are resistant to a herbicide are also tolerant of the herbicide. The terms “resistant” and “tolerant” are to be construed as “tolerant and/or resistant” within the context of the present application.

5

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is the DNA sequence of *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1). The bold underlined nucleotide residues are the targeted residues.

FIG. 1B is the amino acid sequence of *Arabidopsis thaliana* EPSPS protein
10 (SEQ ID NO:2). The bold and underlined amino acid residues are the targeted residues.

FIG. 2 is a list of the *Arabidopsis thaliana* wild-type and mutant EPSPS nucleotide and amino acid sequences in the region of amino acid position 173 to 183; wild-type nucleotide sequence (SEQ ID NO:1) and wild-type amino acid sequence (SEQ ID NO:2); mutant A₁₇₇ nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4); mutant I₁₇₈ nucleotide sequence (SEQ ID NO:5) and amino acid sequence (SEQ ID NO:6); mutant A₁₇₇I₁₇₈ nucleotide sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8); mutant I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:9) and amino acid sequence (SEQ ID NO:10); mutant A₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:11) and amino acid sequence (SEQ ID NO:12); mutant A₁₇₇I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:13) and
20 amino acid sequence (SEQ ID NO:14); mutant V₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:15) and amino acid sequence (SEQ ID NO:16); mutant L₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:17) and amino acid sequence (SEQ ID NO:18); mutant A₁₇₇V₁₇₈ nucleotide sequence (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20); mutant A₁₇₇L₁₈₂ nucleotide sequence (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:22).

FIG. 3A-C is an alignment of the DNA of *Arabidopsis thaliana* EPSPS gene performed by DNASTar (LaserGene), (SEQ ID NO:1) with the nucleotide sequences of *Brassica napus* (SEQ ID NO:23); *Petunia hybrida* (SEQ ID NO:24); and *Zea mays* (SEQ ID NO:25) EPSPS gene. The sequences are aligned using J. Hein method with weighted residue weight table.

30

FIG. 4 is an alignment of the *Arabidopsis thaliana* EPSPS amino acid sequence (SEQ ID NO:2) with the *Brassica napus* (SEQ ID NO:26); *Petunia hybrida* (SEQ ID NO:27); and *Zea mays* (SEQ ID NO:28) EPSPS amino acid sequences. The sequences are aligned using J. Hein method with weighted residue weight table.

FIG. 5 is a list of the mutagenesis primers used, with the targeted codons in bold characters (mutant primer A₁₇₇ (SEQ ID NO:29); mutant primer I₁₇₈ (SEQ ID NO:30);

35

mutant primer A₁₇₇I₁₇₈ (SEQ ID NO:31); mutant primer I₁₇₈S₁₈₂ (SEQ ID NO:32); mutant primer A₁₇₇S₁₈₂ (SEQ ID NO:34); mutant primer A₁₇₇I₁₇₈S₁₈₂ (SEQ ID NO:35); mutant primer V₁₇₇S₁₈₂ (SEQ ID NO:35); mutant primer L₁₇₈S₁₈₂ (SEQ ID NO:36); mutant primer A₁₇₇V₁₇₈ (SEQ ID NO:37); and mutant primer A₁₇₇L₁₈₂ (SEQ ID NO:38)).

5 FIG. 6 is the growth measured by optical density at 600 nm of *Arabidopsis* clones in the presence (+) and absence (-) of 17 mM glyphosate.

FIG. 7 (top panel) is a western blot showing the expression of His-tagged *Bacillus*, *Arabidopsis* wild type (WT) and mutant (AS) EPSPS proteins isolated from cell lysates (L) and eluates (E). Untransformed *Salmonella* as a negative control shows no
10 EPSPS expression. The bottom panel is a silver-stained duplicate gel.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having a mutation in the EPSPS gene, which plant has increased resistance or tolerance to a
15 member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate,
20 wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the
25 phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety by reference herein:
30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or
35 gymnospermous plant, including any woody plant species that grows as a tree or shrub, any herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds, the method comprising application to the field of a herbicide to which the said plants have been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

5.1 RECOMBINAGENIC OLIGONUCLEOBASES

The invention can be practiced with recombinagenic oligonucleobases having the conformations and chemistries described in United States patent No. 5,565,350 to Kmiec (Kmiec I) and U.S. patent No. 5,731,181 (Kmiec II) gene, which are hereby incorporated by reference. Kmiec I teaches a method for introducing specific genetic alterations into a target gene. The recombinagenic oligonucleobases in Kmiec I and/or Kmiec II contain two complementary strands, one of which contains at least one segment of RNA-type nucleotides (an "RNA segment") that are base paired to DNA-type nucleotides of the other strand.

Kmiec II discloses that purine and pyrimidine base-containing non-nucleotides can be substituted for nucleotides. U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789, which are each

hereby incorporated in their entirety, disclose additional recombinagenic molecules that can be used for the present invention. The term "recombinagenic oligonucleobase" is used herein to denote the molecules that can be used in the methods of the present invention and include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in
5 Kmiec II, single stranded oligodeoxynucleotides and other recombinagenic molecules taught in the above noted patents and patent publications.

In one embodiment, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide in which the RNA-type nucleotides of the mixed duplex oligonucleotide are made RNase resistant by replacing the 2'-hydroxyl with a fluoro, chloro or bromo
10 functionality or by placing a substituent on the 2'-O. Suitable substituents include the substituents taught by the Kmiec II. Alternative substituents include the substituents taught by U.S. Patent No. 5,334,711 (Sproat) and the substituents taught by patent publications EP 629 387 and EP 679 657 (collectively, the Martin Applications), which are hereby incorporated by reference. As used herein, a 2' -fluoro, chloro or bromo derivative of a
15 ribonucleotide or a ribonucleotide having a 2'-OH substituted with a substituent described in the Martin Applications or Sproat is termed a "2'-Substituted Ribonucleotide." As used herein the term "RNA-type nucleotide" means a 2'-hydroxyl or 2'-Substituted Nucleotide that is linked to other nucleotides of a mixed duplex oligonucleotide by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.
20 As used herein the term "deoxyribo-type nucleotide" means a nucleotide having a 2'-H, which can be linked to other nucleotides of a MDON by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.

In a particular embodiment of the present invention, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide that is linked solely by unsubstituted
25 phosphodiester bonds. In alternative embodiments, the linkage is by substituted phosphodiester, phosphodiester derivatives and non-phosphorus-based linkages as taught by Kmiec II. In yet another embodiment, each RNA-type nucleotide in the mixed duplex oligonucleotide is a 2'-Substituted Nucleotide. Particular preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-propyloxy, 2'-allyloxy, 2'-
30 hydroxyethyloxy, 2'-methoxyethyloxy, 2'-fluoropropyloxy and 2'-trifluoropropyloxy substituted ribonucleotides. More preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-methoxyethyloxy, and 2'-allyloxy substituted nucleotides. In another embodiment the mixed duplex oligonucleotide is linked by unsubstituted phosphodiester bonds.

35 Although mixed duplex oligonucleotide having only a single type of 2'-substituted RNA-type nucleotide are more conveniently synthesized, the methods of the

invention can be practiced with mixed duplex oligonucleotides having two or more types of RNA-type nucleotides. The function of an RNA segment may not be affected by an interruption caused by the introduction of a deoxynucleotide between two RNA-type trinucleotides, accordingly, the term RNA segment encompasses such an "interrupted RNA segment." An uninterrupted RNA segment is termed a contiguous RNA segment. In an alternative embodiment an RNA segment can contain alternating RNase-resistant and unsubstituted 2'-OH nucleotides. The mixed duplex oligonucleotides preferably have fewer than 100 nucleotides and more preferably fewer than 85 nucleotides, but more than 50 nucleotides. The first and second strands are Watson-Crick base paired. In one embodiment the strands of the mixed duplex oligonucleotide are covalently bonded by a linker, such as a single stranded hexa, penta or tetranucleotide so that the first and second strands are segments of a single oligonucleotide chain having a single 3' and a single 5' end. The 3' and 5' ends can be protected by the addition of a "hairpin cap" whereby the 3' and 5' terminal nucleotides are Watson-Crick paired to adjacent nucleotides. A second hairpin cap can, additionally, be placed at the junction between the first and second strands distant from the 3' and 5' ends, so that the Watson-Crick pairing between the first and second strands is stabilized.

The first and second strands contain two regions that are homologous with two fragments of the target EPSPS gene, *i.e.*, have the same sequence as the target gene. A homologous region contains the nucleotides of an RNA segment and may contain one or more DNA-type nucleotides of connecting DNA segment and may also contain DNA-type nucleotides that are not within the intervening DNA segment. The two regions of homology are separated by, and each is adjacent to, a region having a sequence that differs from the sequence of the target gene, termed a "heterologous region." The heterologous region can contain one, two or three mismatched nucleotides. The mismatched nucleotides can be contiguous or alternatively can be separated by one or two nucleotides that are homologous with the target gene. Alternatively, the heterologous region can also contain an insertion or one, two, three or of five or fewer nucleotides. Alternatively, the sequence of the mixed duplex oligonucleotide may differ from the sequence of the target gene only by the deletion of one, two, three, or five or fewer nucleotides from the mixed duplex oligonucleotide. The length and position of the heterologous region is, in this case, deemed to be the length of the deletion, even though no nucleotides of the mixed duplex oligonucleotide are within the heterologous region. The distance between the fragments of the target gene that are complementary to the two homologous regions is identically the length of the heterologous region when a substitution or substitutions is intended. When the heterologous region contains an insertion, the homologous regions are thereby separated in

the mixed duplex oligonucleotide farther than their complementary homologous fragments are in the gene, and the converse is applicable when the heterologous region encodes a deletion.

The RNA segments of the mixed duplex oligonucleotides are each a part of a homologous region, *i.e.*, a region that is identical in sequence to a fragment of the target gene, which segments together preferably contain at least 13 RNA-type nucleotides and preferably from 16 to 25 RNA-type nucleotides or yet more preferably 18-22 RNA-type nucleotides or most preferably 20 nucleotides. In one embodiment, RNA segments of the homology regions are separated by and adjacent to, *i.e.*, "connected by" an intervening DNA segment. In one embodiment, each nucleotide of the heterologous region is a nucleotide of the intervening DNA segment. An intervening DNA segment that contains the heterologous region of a mixed duplex oligonucleotide is termed a "mutator segment."

The change to be introduced into the target EPSPS gene is encoded by the heterologous region. The change to be introduced into the EPSPS gene may be a change in one or more bases of the EPSPS gene sequence or the addition or deletion of one or more bases.

In another embodiment of the present invention, the recombinagenic oligonucleobase is a single stranded oligodeoxynucleotide mutational vector or SSOMV, which is disclosed in International Patent Application PCT/US00/23457, which is incorporated by reference in its entirety. The sequence of the SSOMV is based on the same principles as the mutational vectors described in U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789. The sequence of the SSOMV contains two regions that are homologous with the target sequence separated by a region that contains the desired genetic alteration termed the mutator region. The mutator region can have a sequence that is the same length as the sequence that separates the homologous regions in the target sequence, but having a different sequence. Such a mutator region can cause a substitution. Alternatively, the homologous regions in the SSOMV can be contiguous to each other, while the regions in the target gene having the same sequence are separated by one, two or more nucleotides. Such a SSOMV causes a deletion from the target gene of the nucleotides that are absent from the SSOMV. Lastly, the sequence of the target gene that is identical to the homologous regions may be adjacent in the target gene but separated by one two or more nucleotides in the sequence of the SSOMV. Such an SSOMV causes an insertion in the sequence of target gene.

The nucleotides of the SSOMV are deoxyribonucleotides that are linked by unmodified phosphodiester bonds except that the 3' terminal and/or 5' terminal internucleotide linkage or alternatively the two 3' terminal and/or 5' terminal internucleotide linkages can be a phosphorothioate or phosphoramidate. As used herein an internucleotide linkage is the linkage between nucleotides of the SSOMV and does not include the linkage between the 3' end nucleotide or 5' end nucleotide and a blocking substituent, see *supra*. In a specific embodiment the length of the SSOMV is between 21 and 55 deoxynucleotides and the lengths of the homology regions are, accordingly, a total length of at least 20 deoxynucleotides and at least two homology regions should each have lengths of at least 8 deoxynucleotides.

The SSOMV can be designed to be complementary to either the coding or the non-coding strand of the target gene. When the desired mutation is a substitution of a single base, it is preferred that both the mutator nucleotide be a pyrimidine. To the extent that is consistent with achieving the desired functional result it is preferred that both the mutator nucleotide and the targeted nucleotide in the complementary strand be pyrimidines. Particularly preferred are SSOMV that encode transversion mutations, *i.e.*, a C or T mutator nucleotide is mismatched, respectively, with a C or T nucleotide in the complementary strand.

In addition to the oligodeoxynucleotide the SSOMV can contain a 5' blocking substituent that is attached to the 5' terminal carbons through a linker. The chemistry of the linker is not critical other than its length, which should preferably be at least 6 atoms long and that the linker should be flexible. A variety of non-toxic substituents such as biotin, cholesterol or other steroids or a non-intercalating cationic fluorescent dye can be used. Particularly preferred as reagents to make SSOMV are the reagents sold as Cy3TM and Cy5TM by Glen Research, Sterling VA, which are blocked phosphoramidites that upon incorporation into an oligonucleotide yield 3,3,3',3'-tetramethyl N,N'-isopropyl substituted indomonocarbocyanine and indodicarbocyanine dyes, respectively. Cy3 is the most preferred. When the indocarbocyanine is N-oxyalkyl substituted it can be conveniently linked to the 5' terminal of the oligodeoxynucleotide through as a phosphodiester with a 5' terminal phosphate. The chemistry of the dye linker between the dye and the oligodeoxynucleotide is not critical and is chosen for synthetic convenience. When the commercially available Cy3 phosphoramidite is used as directed the resulting 5' modification consists of a blocking substituent and linker together which are a N-hydroxypropyl, N'-phosphatidylpropyl 3,3,3',3'-tetramethyl indomonocarbocyanine.

In the preferred embodiment the indocarbocyanine dye is tetra substituted at the 3 and 3' positions of the indole rings. Without limitation as to theory these substitutions

prevent the dye from being an intercalating dye. The identity of the substituents at these positions are not critical. The SSOMV can in addition have a 3' blocking substituent. Again the chemistry of the 3' blocking substituent is not critical.

5 5.2 THE LOCATION AND TYPE OF MUTATION INTRODUCED INTO THE EPSPS GENE

In one embodiment of the present invention, the *Arabidopsis thaliana* EPSPS gene (see Figure 1A) and corresponding EPSPS enzyme (see Figure 1B) comprises a mutation at one or more amino acid residues selected from the group consisting of Leu₁₇₃,
10 Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈, or at an analogous position in an EPSPS paralog, and the mutation results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ - Phe
- (ii) Gly₁₇₇ - Ala or Ile
- 15 (iii) Thr₁₇₈ - Ile or Val or Leu
- (iv) Ala₁₇₉ - Gly
- (v) Met₁₈₀ - Cys
- (vi) Arg₁₈₁ - Leu or Ser
- (vii) Pro₁₈₂ - Leu or Ser
- 20 (viii) Ser₉₈ -Asp
- (ix) Ser₂₅₅ -Ala
- (x) Leu₁₉₈ -Lys.

In another embodiment of the present invention, within the EPSPS gene product, the amino acid residue to be changed is Leu within the contiguous sequence Leu-
25 Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg
30 (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to
35 Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the

contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

5 Alternatively, and/or additionally, the mutation may result in the replacement of any amino acid at positions corresponding to 256, 284-288 and 353-356 with respect to the EPSPS protein depicted in Figure 1B (SEQ ID NO. 2).

In specific embodiments of the present invention, the EPSPS gene is mutated at amino acid position 177 in which Gly is replaced by Ala. Another specific embodiment
10 is the substitution of Thr at amino acid position 178 by Ile. A further specific embodiment comprises a mutation at amino acid position 177 in which Gly is replaced by Ala, plus the additional substitution of Thr at amino acid position 178 by Ile. Other specific embodiments of the present invention are directed to mutations at amino acid position 178, in which Thr is replaced by Ile, plus the additional mutation at position 182, in which Pro is
15 replaced by Ser. Other embodiments include the substitution of Gly at amino acid position 177 by Ala, plus the additional mutation at amino acid position 182, in which Pro is substituted by Ser. Other mutated EPSPS sequences comprise the substitution of Gly at position 177 by Ala, plus the substitution at position 178, in which Thr is replaced by Ile, plus the additional substitution of Pro at amino acid position 182 by Ser. Another
20 embodiment is the substitution of Thr at amino acid position 178 by Val and the additional mutation at amino acid position 182, in which Pro is replaced by Ser. A further specific embodiment includes the substitution of Thr at position 178 by Leu, plus the mutation at amino acid position 182, in which Pro is replaced by Ser. A further embodiment includes, the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the
25 substitution of Thr at position 178 by Val. The invention also embodies the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the replacement of Thr at amino acid position 178 by Leu (see Figure 2).

The foregoing mutations in the EPSPS gene were described using the *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1) and protein (SEQ ID NO:2). The
30 present invention also encompasses mutant EPSPS genes of other species (paralogs). However, due to variations in the EPSPS genes of different species, the number of the amino acid residue to be changed in one species may be different in another species. Nevertheless, the analogous position is readily identified by one of skill in the art by sequence homology. For example, Figure 3A-C shows the aligned nucleotide sequences
35 and Figure 4 shows the aligned amino acid sequences of four paralogs of the EPSPS gene, *Arabidopsis thaliana*, *Zea mays*, *Petunia hybrida*, and *Brassica napus*. Thus, the analogous

positions in *Zea mays* are Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂. Thus, the *Zea mays* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₉₇ - Phe
- 5 (ii) Gly₁₀₁ - Ala or Ile
- (iii) Thr₁₀₂ - Ile or Val or Leu
- (iv) Ala₁₀₃ - Gly
- (v) Met₁₀₄ - Cys
- (vi) Arg₁₀₅ - Leu or Ser
- 10 (vii) Pro₁₀₆ - Leu or Ser
- (viii) Ser₂₃ -Asp
- (ix) Ser₁₇₉ -Ala
- (x) Leu₁₂₂ -Lys.

In another embodiment of the present invention, within the *Zea mays* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In *Brassica napus*, the analogous amino acid positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the *Brassica napus* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₁₆₉ - Phe

- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys

10 In another embodiment of the present invention, within the *Brassica napus* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In *Petunia hybrida* the analogous positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the *Petunia hybrida* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys

- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys

5

In another embodiment of the present invention, within the *Petunia hybrida* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

25

5.3 THE DELIVERY OF RECOMBINAGENIC OLIGONUCLEOBASES INTO PLANT CELLS

30

Any commonly known method can be used in the methods of the present invention to transform a plant cell with a recombinagenic oligonucleobases. Illustrative methods are listed below.

5.3.1 MICROCARRIERS AND MICROFIBERS

35

The use of metallic microcarriers (microspheres) for introducing large fragments of DNA into plant cells having cellulose cell walls by projectile penetration is well known to those skilled in the relevant art (henceforth biolistic delivery). United States Patent Nos. 4,945,050; 5,100,792 and 5,204,253 describe general techniques for selecting microcarriers and devices for projecting them.

Specific conditions for using microcarriers in the methods of the present invention are described in International Publication WO 99/07865. In an illustrative technique, ice cold microcarriers (60 mg/ml), mixed duplex oligonucleotide (60 mg/ml) 2.5 M CaCl₂ and 0.1 M spermidine are added in that order; the mixture gently agitated, *e.g.*, by vortexing, for 10 minutes and let stand at room temperature for 10 minutes, whereupon the microcarriers are diluted in 5 volumes of ethanol, centrifuged and resuspended in 100% ethanol. Good results can be obtained with a concentration in the adhering solution of 8-10 µg/µl microcarriers, 14-17 µg/ml mixed duplex oligonucleotide, 1.1-1.4 M CaCl₂ and 18-22 mM spermidine. Optimal results were observed under the conditions of 8 µg/µl microcarriers, 16.5 µg/ml mixed duplex oligonucleotide, 1.3 M CaCl₂ and 21 mM spermidine.

Recombinagenic oligonucleobases can also be introduced into plant cells for the practice of the present invention using microfibers to penetrate the cell wall and cell membrane. U.S. Patent No. 5,302,523 to Coffee et al. describes the use of 30 x 0.5 µm and 10 x 0.3 µm silicon carbide fibers to facilitate transformation of suspension maize cultures of Black Mexican Sweet. Any mechanical technique that can be used to introduce DNA for transformation of a plant cell using microfibers can be used to deliver recombinagenic oligonucleobases for transmutation.

An illustrative technique for microfiber delivery of a recombinagenic oligonucleobase is as follows: Sterile microfibers (2 µg) are suspended in 150 µl of plant culture medium containing about 10 µg of a mixed duplex oligonucleotide. A suspension culture is allowed to settle and equal volumes of packed cells and the sterile fiber/nucleotide suspension are vortexed for 10 minutes and plated. Selective media are applied immediately or with a delay of up to about 120 hours as is appropriate for the particular trait.

5.3.2 PROTOPLAST ELECTROPORATION

In an alternative embodiment, the recombinagenic oligonucleobases can be delivered to the plant cell by electroporation of a protoplast derived from a plant part. The protoplasts are formed by enzymatic treatment of a plant part, particularly a leaf, according to techniques well known to those skilled in the art. *See, e.g.*, Gallois et al., 1996, in Methods in Molecular Biology 55:89-107, Humana Press, Totowa, NJ; Kipp et al., 1999, in Methods in Molecular Biology 133:213-221, Humana Press, Totowa, NJ. The protoplasts need not be cultured in growth media prior to electroporation. Illustrative conditions for electroporation are 3 x 10⁵ protoplasts in a total volume of 0.3 ml with a concentration of recombinagenic oligonucleobase of between 0.6 - 4 µg/mL.

5.3.3 WHISKERS AND MICROINJECTION

In yet another alternative embodiment, the recombinagenic oligonucleobase can be delivered to the plant cell by whiskers or microinjection of the plant cell. The so called whiskers technique is performed essentially as described in Frame et al., 1994, Plant J. 6:941-948. The recombinagenic oligonucleobase is added to the whiskers and used to transform the plant cells. The recombinagenic oligonucleobase may be co-incubated with plasmids comprising sequences encoding proteins capable of forming recombinase complexes in plant cells such that recombination is catalyzed between the oligonucleotide and the target sequence in the EPSPS gene.

10

5.4 SELECTION OF GLYPHOSATE RESISTANT PLANTS

Plants or plant cells can be tested for resistance or tolerance to a herbicide using commonly known methods in the art, e.g., by growing the plant or plant cell in the presence of a herbicide and measuring the rate of growth as compared to the growth rate in the absence of the herbicide.

15

6. EXAMPLE

The following experiments demonstrate the production of mutant *Arabidopsis thaliana* EPSPS genes which are resistant to the herbicide glyphosate and which allows the plant cells to maintain a growth rate

20

6.1 MATERIAL AND METHODS

6.1.1 ISOLATION OF *ARABIDOPSIS THALIANA* EPSPS cDNA

A 1.3 kb DNA fragment was amplified by PCR from an *Arabidopsis* cDNA library using the primers AtEXPEXPM1 and AtEXPEXP2CM-2. The two primers were designed to amplify the cDNA from the mature peptide to the termination codon. The 5' primer AtEXPEXPM1 contains an XbaI site (underlined) and the 3' primer AtEXPEXP2CM-2 contains a BglII site (underlined), sites which will be of use for cloning of the fragment into the expression vector.

30

AtEXPEXPM1

5'-GCTCTAGAGAAAGCGTCGGAGATTGTACTT-3' (SEQ ID NO:40)

AtEXPEXP2CM-2

35 5'-GCAGATCTGAGCTCTTAGTGCTTTGTGATTCTTTCAAGTAC-3' (SEQ ID NO:41)

flanking primer (5'ATEPS-198: 5'- GAAAGCGTCGGAGATTGTAC-3' (SEQ ID NO:44)) and one of the mutation-carrying primers (see Figure 5).

The 353bp PCR fragments obtained were purified (Qiagen PCR Purification kit) and their sequence confirmed. The fragments were then digested with PstI (underlined in the primer sequences) and BamHI and ligated to the pAtEPS-12 vector, which had itself been previously digested with PstI and BamHI. JM109 (Promega) competent cells were used for the transformation and plated onto chloramphenicol-containing LB plates. Clones from each mutagenesis experiment were then isolated and their sequence confirmed.

6.1.5 GLYPHOSATE RESISTANCE ASSAYS

Electrocompetent cells of SA4247, a LacZ - *Salmonella typhi* strain, were prepared according to well known procedures (see Current Protocols in Molecular Biology, (Wiley and Sons, Inc.)). 30 μ l of SA4247 competent cells were electroporated with 20 ng of each plasmid DNA encoding *Arabidopsis* wild-type and mutant EPSPS proteins, *Bacillus* wild-type EPSPS, along with a mock transfection as a control. The settings for electroporation were 25 μ F, 2.5KV and 200 ohms. After electroporation, the cells were transferred into 15 mls culture tube and supplemented with 970 μ l of SOC medium. The cultures were incubated for 1 ½ hours at 37°C at 225 rpm. 50 μ l of each culture were plated onto LB plates containing 17 μ g/ml chloramphenicol (in duplicates) and incubated overnight at 37°C. On the following day, 5 colonies of each plate were picked and transferred onto M9 plates and incubated overnight at 37°C.

Colonies from the overnight incubation on solid M9 were inoculated into 4 ml of liquid M9 medium and grown overnight at 37°C. On the following day, 25 ml of liquid M9 medium containing chloramphenicol, IPTG and 17 mM or 0 mM Glyphosate (Aldrich, 33775-7) were inoculated with 1-2 mls of each overnight culture (in duplicates), the starting OD (at 600 nm) was measured and all the cultures were normalized to start at the same OD. An OD measurement was taken every hour for seven hours. As a control of the bacterial growth, a culture of untransformed *Salmonella* was also inoculated into plain LB medium. In two independent experiments, the clones A₁₇₇I₁₇₈, A₁₇₇V₁₇₈, A₁₇₇L₁₇₈ and I₁₇₇ did not grow in M9 medium, therefore the glyphosate-resistance assays could not be performed on them.

6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES

One milliliter of overnight culture of each of the bacterial clones is inoculated into 100 ml of liquid LB medium containing chloramphenicol. The cells were

allowed to grow at 37°C until they reached an OD of 0.5-0.7 (approximately 3 ½ hours). IPTG was then added to the cultures to a concentration of 1.0 mM. The cells were grown five additional hours. They were then pelleted at 4000 rpm for 20 minutes at 4°C.

The isolation and the purification of the His-tagged proteins were performed following the Qiagen Ni-NTA Protein Purification System. Cell lysates and eluates were run in duplicates on 12.5% acrylamide gels. One of the gels was silver-stained for immediate visualization, the second gel was transferred onto Millipore Immobilon-P membrane, and blocked overnight in 5% milk in TBS-T. The membrane was then exposed to Anti-His primary antibody solution (Amersham Pharmacia biotech, cat# 37-4710), followed by exposure to Anti-Mouse-IgG secondary antibody solution. (NIF825, from Amersham Pharmacia biotech ECL Western blotting analysis system, cat# RPN2108). Washes and detection reactions were performed according to the manufacturer instructions. Autoradiograms were developed after 5 minutes exposure.

6.2 RESULTS

Cells containing a mutation in the EPSPS gene produced cells that were both resistant to the herbicide glyphosate and that had a substantially similar growth rate in the absence or presence of glyphosate, as compared to the wild-type cells, irrespective of the presence of glyphosate (see Figure 6).

It was also demonstrated that the *Arabidopsis* clones containing a mutant EPSPS gene expressed the mutant protein at substantially the same level as the wild-type protein (see Figure 7).

The invention claimed and described herein is not to be limited in scope by the specific embodiments, including but not limited to the deposited microorganism embodiments, herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference.

WE CLAIM:

1. A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product and which plant has substantially normal growth as compared to a
5 plant expressing the wild-type EPSPS gene product.
2. A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product, which gene product has substantially the same level of catalytic activity as compared to the wild-type gene product.
10
3. The plant according to claim 1 or 2 in which the herbicide is a member of the phosphonomethylglycine family.
4. The plant according to claim 3 in which the member of the
15 phosphonomethylglycine family is glyphosate.
5. The plant according to claim 1 or 2 in which the EPSPS gene is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in *Arabidopsis* or
20 at an analogous amino acid residue in an EPSPS paralog.
6. The plant according to claim 5 in which the positions in the *Zea mays* paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.
25
7. The plant according to claim 5 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
8. The plant according to claim 5 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
30
9. The plant according to claim 1 or 2 in which the plant is selected from the
35 group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape,

canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

10. The plant according to claim 5 in which the mutated gene results in one
5 or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ - Phe
- (ii) Gly₁₇₇ - Ala or Ile
- (iii) Thr₁₇₈ - Ile or Val or Leu
- 10 (iv) Ala₁₇₉ - Gly
- (v) Met₁₈₀ - Cys
- (vi) Arg₁₈₁ - Leu or Ser
- (vii) Pro₁₈₂ - Leu or Ser
- (viii) Ser₉₈ -Asp
- 15 (ix) Ser₂₅₅ -Ala
- (x) Leu₁₉₈ -Lys.

11. The plant according to claim 6 in which the mutated gene results in one
or more of the following amino acid substitutions in the EPSPS enzyme in comparison with
20 the wild-type sequence:

- (i) Leu₉₇ - Phe
- (ii) Gly₁₀₁ - Ala or Ile
- (iii) Thr₁₀₂ - Ile or Val or Leu
- (iv) Ala₁₀₃ - Gly
- 25 (v) Met₁₀₄ - Cys
- (vi) Arg₁₀₅ - Leu or Ser
- (vii) Pro₁₀₆ - Leu or Ser
- (viii) Ser₂₃ -Asp
- (ix) Ser₁₇₉ -Ala
- 30 (x) Leu₁₂₂ -Lys.

12. The plant according to claim 7 in which the mutated gene results in one
or more of the following amino acid substitutions in the EPSPS enzyme in comparison with
the wild-type sequence:

- 35 (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile

- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys.

10 13. The plant according to claim 8 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys.

25 14. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising

- a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and
- b. identifying a cell having a mutated EPSPS gene, which cell has substantially normal growth as compared to a corresponding wild-type plant cell.

30 15. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising

- a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and

b. identifying a cell having a mutated EPSPS gene, which encoded mutant EPSPS protein has substantially the same catalytic activity as compared to a corresponding wild-type EPSPS protein.

5 16. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is a mixed duplex nucleotide or a SSMOV.

17. The method according to claim 16 in which the mixed duplex nucleotide contains a first homologous region which has a sequence identical to the sequence of at
10 least 6 base pairs of the first fragment of the target EPSPS gene and a second homologous region which has a sequence identical to the sequence of at least 6 based pairs of a second fragment of the target EPSPS gene, and an intervening region which contains at least one nucleobase heterologous to the target EPSPS gene, which intervening region connects the first and second homologous region.

15 18. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is introduced by electroporation.

19. The method according to claim 14 or 15 which the mutant EPSPS gene
20 is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in *Arabidopsis* or at an analogous amino acid residue in an EPSPS paralog.

20. The plant according to claim 19 in which the positions in the *Zea mays*
25 paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.

21. The plant according to claim 19 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆,
30 Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.

22. The plant according to claim 19 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆,
Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.

35

23. The plant according to claim 14 or 15 in which the plant is selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape, turf grasses and *Brassica* sp.

5

24. An isolated mutant EPSPS protein comprising the amino acid sequence depicted in SEQ ID NO:2, in which amino acid position Leu₁₇₃ is replaced with Phe, Gly₁₇₇ is replaced with Ala or Ile, Thr₁₇₈ is replaced with Ile or Val or Leu, Ala₁₇₉ is replaced with Gly, Met₁₈₀ is replaced with Cys, Arg₁₈₁ is replaced with Leu or Ser, Pro₁₈₂ is replaced with
10 Leu or Ser, Ser₉₈ is replaced with Asp, Ser₂₅₅ is replaced with Ala or Leu₁₉₈ is replaced with Lys, which mutant EPSPS protein has increased resistance or tolerance to a herbicide, which herbicide is a member of the phosphonomethylglycine family.

15

20

25

30

35

Variable	Mean	SD	Min	Max
Age	35.2	12.5	18	65
Gender	Male	10	0	20
Education	High School	15	0	30
Occupation	Unemployed	25	0	50
Marital Status	Married	15	0	30
Religious Belief	Christian	10	0	20
Political Affiliation	Democrat	15	0	30
Health Status	Good	10	0	20
Income Level	Low	15	0	30
Home Ownership	Rent	10	0	20
Vehicle Ownership	Yes	15	0	30
Travel Frequency	Monthly	10	0	20
Communication Frequency	Daily	15	0	30
Stress Level	Low	10	0	20
Life Satisfaction	High	15	0	30
Community Involvement	Yes	10	0	20
Volunteer Hours	10	5	0	20
Charitable Donations	\$50	20	0	100
Political Participation	Yes	10	0	20
Environmental Awareness	High	15	0	30
Health Insurance	Medicaid	10	0	20
Food Security	Yes	15	0	30
Housing Stability	Yes	10	0	20
Job Satisfaction	Low	15	0	30
Work-Life Balance	Good	10	0	20
Financial Stability	Low	15	0	30
Emotional Well-being	High	10	0	20
Social Support	Yes	15	0	30
Life Goals	Clear	10	0	20
Personal Growth	Yes	15	0	30
Resilience	High	10	0	20
Optimism	Yes	15	0	30
Gratitude	High	10	0	20
Forgiveness	Yes	15	0	30
Empathy	High	10	0	20
Compassion	Yes	15	0	30
Patience	High	10	0	20
Kindness	Yes	15	0	30
Generosity	High	10	0	20
Humility	Yes	15	0	30
Modesty	High	10	0	20
Shyness	Yes	15	0	30
Introversion	High	10	0	20
Extroversion	Yes	15	0	30
Sensitiveness	High	10	0	20
Emotional Stability	Yes	15	0	30
Impulsivity	Low	10	0	20
Recklessness	Yes	15	0	30
Risk-taking	High	10	0	20
Adventurousness	Yes	15	0	30
Curiosity	High	10	0	20
Imagination	Yes	15	0	30
Creativity	High	10	0	20
Innovation	Yes	15	0	30
Originality	High	10	0	20
Uniqueness	Yes	15	0	30
Individuality	High	10	0	20
Self-expression	Yes	15	0	30
Authenticity	High	10	0	20
Genuineness	Yes	15	0	30
Sincerity	High	10	0	20
Honesty	Yes	15	0	30
Integrity	High	10	0	20
Trustworthiness	Yes	15	0	30
Reliability	High	10	0	20
Dependability	Yes	15	0	30
Accountability	High	10	0	20
Responsibility	Yes	15	0	30
Commitment	High	10	0	20
Dedication	Yes	15	0	30
Devotion	High	10	0	20
Loyalty	Yes	15	0	30
Fidelity	High	10	0	20
Constancy	Yes	15	0	30
Perseverance	High	10	0	20
Persistence	Yes	15	0	30
Endurance	High	10	0	20
Stamina	Yes	15	0	30
Fortitude	High	10	0	20
Bravery	Yes	15	0	30
Courage	High	10	0	20
Valor	Yes	15	0	30
Gallantry	High	10	0	20
Heroism	Yes	15	0	30
Chivalry	High	10	0	20
Knightliness	Yes	15	0	30
Politeness	High	10	0	20
Courtesy	Yes	15	0	30
Decency	High	10	0	20

DNA sequence:

cccttcacgtctttttagaaccacccattatctttcttagggcccaattgaaaaccacattttctttcacctaaccac
caaagccttgacatgttgacgtgaacaccaaactaacacgtgtcatactgccagtgggttatgataaatgctcataccat
accagagtcataagagtttttgggtgggtgaaagatttgacggatgccttcttctcatttctcaccacactccctccaaacc
aacaaaatgtttatattagcaaagccgccaaagtgtaaacgaaagttataaatcttctgtgatcttacgtaattg
gaggaagatcaaaattttcaatccccattcttcgattgcttcaattgaagtttctccg

[transit peptide start]

ATGGCGCAAGTTAGCAGAACTGCAATGGTGTGCAGAACCCATCTCTTATCTCCAATCTCTCGAAATCCAGTCAACGCAA
ATCTCCCTTATCGGTTTCTCTGAAGACGCAGCAGCATCCACGAGCTTATCCGATTTCTGTCGTCGTGGGGATTGAAGAAGA
GTGGGATGACGTTAATTGGCTCTGAGCTTCGTCCTCTTAAGGTCATGTCTTCTGTTCCACGGCGGAG

[mature peptide starts]

AAAGCGTCGGAGATTGTACTTCAACCCATTAGAGAAATCTCCGGTCTTATTAAGCTTCCTGGCTCCAAGTCTCTATCAAA
TCGGATCCTGCTTCTCGCTGCTCTGTCTGAGGTATATATCACTTCGTTTCGTCCTTCTCTGTAATCTGAACCTTAGATTAT
AAAGATTGATACTTTACCATTTTGCTGTGGTTTTATAGGGAACAACCTGTAGTGGACAACCTTGTGTAATAGCGATGACATC
AATTACATGCTTGATGCGTTGAAGAGATTGGGACTTAATGTGGAACTGACAGTGAAAATAATCGTGTGTAGTTGAAGG
ATGTGGCGGGATATTCCCGACTTCCATAGATTCAAAGAGTGATATCGAACTTTACCTCGGTAATGCAGGAACAGCAATGC
GTCCACTTACCGCTGCGGTCACTGCTGCAGGTGGAACGCAAGGTAGATTGAAGGAGTTGATGCTTCTGGTATTTGATG
TTTAAGGAATGGAGCTTTTGTGTATGCTTATGATCCATTTATTCAGTTATGTGCTTGATGGGGTGCCTCGTATGAGAG
AAAGACCTATAGGGGATTGGTGTGGTCTTAAGCAGCTTGGTGCTGATGTTGAATGTACTCTTGGAACTAACTGCCCT
CCTGTTCTGTGCAACGCTAATGGTGGCTTCCCGGTGGAAGGTTAGATCTTGCAAATGGCATGTGAATATGTAATCTCG
TTCCTTACTCTATGAACACTTGCAGAAATGTGTGTTTCATATAGCCTTAGCTTGACAAGATTTCACTTTTAACTACTC
TCAACGGATGGATCCTAAAATAGAATCGGATTTGGTGATTGGTTTTCTGTTCTCGATTACCGTTTTCTGTTGATGATTTCT
TGATTAACAATTAGGAGACATGTTATGCATTGTCAGGTGAAGCTTTCTGGATCAATTAGTAGTCAGTACTTGACTGCTCT
GCTCATGTCTGCTCCCTTAGCTCTTGGAGACGTCGAGATTGAGATTGCGATAAATTAATTTCTGTTCCATATGTTGAA
TGACATTGAAGTTGATGGAACGTTTCGGGGTTAGTGTGAGCATAGTATAGCTGGGATCGTTTTCTTGTCAAGGGCGGG
CAAAAATACAAGTAGGAGTTATTCTTTTCTCTTTCTGAAATCACATCCCTTAGCTTGACAATATAATGACTAAAAGG
TGAATGATTCAAGTCTCCGGGTAATGCGTATGTAGAAGGTGATGCTTCTAGTGCATGTTATTTCTGGCTGGTGCTGCCA
TTACCGGTGAACTGTCAAGTCGAAGGTTGTGGAACCTCAGCTTGCAGGTAATATTTGTACACTGAATCATCGACGAG
GCTGTTAAGTTTATAGTGAAATTCGTCTAGGTCAAAGTTTCATCTTTTGACAAGTTGTATATAACATATTCGCAAGATTC
TAAGCTCAATTTTGTGATGAATCTCTAGGGAGATGTAAATTCGCCGAGGTCCTTGAGAAAATGGGATGTAAAGTGTC
TGGACAGAGAACAGTGTGACTGTGACAGGACCACCTAGAGATGCTTTTGGAAATGAGACACTTGCGGGCTATTGATGTCAA
CATGAACAAAATGCCTGATGTAGCCATGACCCTTGCCGTCGTTGCTCTCTTTGCTGACGGTCCAACCACCTTAGAGATG
GTAAGTAAAAAGCTCTCTCTTATAATTAAGGTTTCTCAATATTCATGATCACTTAATCTGTTTGGTTAATATAGTGGCT
AGCTGGAGAGTAAAGGAGACAGAAAGGATGATTGCCATTTGCACAGAGCTTAGAAAAGTAAGAGATTCTTATCTCTCT
TTCTGTCTCTTGACAGTGCTCATTCTAAGTAATTAGCTCATAAATTTGTGTGTTTGTGTTTCAGCTGGGAGCTACAGTGGA
AGAAGGTTCAAGATTATGTGTGATAACTCCGCCAAAAAGGTGAAAACGGCAGAGATTGATACATATGATGATCATAGAA
TGGCAATGGCATTCTCTCTTGCAGCTTGTGCTGATGTTCCAATCACCATCAACGACTCTGGTTGCACCAGGAAAACCTTC
CCGACTACTTCCAAGTACTTGAAAGAATCACAAAGCACTAAacaataaactctgtttttcttctgatccaagctt

FIG. 1A

Protein sequence:

MAQVSRICNGVQNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIGSELRLPKVMSSVSTAE
KASEIVLQPIREISGLIKLPGSKSLSNRIILLAAALSEGTTVVDNLLNSDDINYMLDALKRLGLNVETDSENNRAVV
EGCGGIFPASIDSKSDIELYLGNAGTAMRPLTAAVTAAGGNASYVLDGVPRMRERPIGDLVVGLKQLGADVECTLG
TNCPPVRVNANGGLPGGKVKLSGSISSQYLALLMSAPLALGDVEIEIVDKLISVPYVEMTLKLMERFGVSVESD
SWDRFFVKGGQKYKSPGNAYVEGDASSACYFLAGAAITGETVTVEGCGTTSLQGDVKFAEVLEKMGCKVSWTENS
TVTGPPRDAFGMRHLRAIDVNMNKMPPDVAMTLAVVALFADGPTTIRDVASWRVKETERMIAICTELRKLGAATVEEG
SDYCVITPPKKVKTAIEDTYDDHRMAMAFSLAACADVPITINDSGCTRKTFPDYFQVLERITKH

FIG. 1B

Arabidopsis thaliana wild type sequence:

Position	173	174	175	176	177	178	179	180	181	182	183
	L	G	N	A	G	T	A	M	R	P	L
	CTC	GGT	AAT	GCA	GGA	ACA	GCA	ATG	CGT	CCA	CTT

Arabidopsis thaliana mutant sequences:

Name

A ₁₇₇	CTC	GGT	AAT	GCA	GCA	ACA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	T	A	M	R	P	L

I ₁₇₈	CTC	GGT	AAT	GCA	GGA	ATA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	G	I	A	M	R	P	L

A ₁₇₇ I ₁₇₈	CTC	GGT	AAT	GCA	GCA	ATA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	I	A	M	R	P	L

I ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GGA	ATA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	G	I	A	M	R	S	L

A ₁₇₇ S ₁₈₂	CTC	GGT	AAT	GCA	GCA	ACA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	A	T	A	M	R	S	L

A ₁₇₇ I ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GCA	ATA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	A	I	A	M	R	S	L

V ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GGA	GTA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	G	V	A	M	R	S	L

L ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GGA	TTA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	G	L	A	M	R	S	L

A ₁₇₇ V ₁₇₈	CTC	GGT	AAT	GCA	GCA	GTA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	V	A	M	R	P	L

A ₁₇₇ L ₁₇₈	CTC	GGT	AAT	GCA	GCA	TTA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	L	A	M	R	P	L

FIG. 2

92	600	610	620	630	640	650	660	670	680	690	atpsscdna.seq
80	CTTATGGGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										bnepsdca.seq
80	CTTATGGGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										petaroacdna.seq
80	CTTATGGGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										zmpsps.seq
84	CTTATGGGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										
692	700	710	720	730	740	750	760	770	780	790	atpsscdna.seq
680	GACCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										bnepsdca.seq
680	GACCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										petaroacdna.seq
680	GACCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										zmpsps.seq
464	GACCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										
792	800	810	820	830	840	850	860	870	880	890	atpsscdna.seq
780	TGCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										bnepsdca.seq
780	TGCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										petaroacdna.seq
564	TGCTCCTGCTGCTGATGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										zmpsps.seq
892	900	910	920	930	940	950	960	970	980	990	atpsscdna.seq
880	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										bnepsdca.seq
880	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										petaroacdna.seq
880	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										zmpsps.seq
664	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										
992	1000	1010	1020	1030	1040	1050	1060	1070	1080	1090	atpsscdna.seq
980	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										bnepsdca.seq
980	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										petaroacdna.seq
764	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										zmpsps.seq
1092	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	atpsscdna.seq
1080	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										bnepsdca.seq
1080	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										petaroacdna.seq
364	GTTAGTGTGAGCAGCAGTGTGAGAGAGACCTATAGGGGATTTGGTTGGTCTTAAGCAGCTTGGTCTGATGTTGAAGTACTCTTGGAACTAACT										zmpsps.seq

FIG. 3B

atepspcDNA.SEQ
bnepsDNA.SEQ
petaroacDNA.SEQ
zmepsps.SEQ

	10	20	30	40	50	60	70	80	90	100	
1	MAQVSRICNGVQNP	SLISNLSKSSQKSP	SLKTOQHPRAYPI	SSSWGLKKS	SGNTLIGSELR	-----	PLKVNSSVSTA	EKASEIVLQPI	REISGLIKL	PGSKLSN	atepsps. PRO
1	MAQSSRICIGVQNP	CVIISNLSKSNQNK	SPFSVLKTHQ	-----	PRASSWGLKKS	SGTMLNGSVTR	-----	PKVVTASVSTSE	XASEIVLQPI	REISGLIKL	PGSKLSN
1	MAQINNMAGIQTL	NPNSNFHKPQ	PKSSPLVFGSKK	-----	LKNSA	-----	NSMLVLKKDS	IFMQKFCFS	FRISASVATA	KQPSSEIVLQPI	KEISGTVKL
1	AG	-----	-----	-----	-----	-----	-----	-----	-----	-----	PGSKLSN
											zmeppsps. PRO
104	RIILLAAAL	SEGTTVVDNLLN	SDINMYLMDAL	KRLGNVETD	SENPAVVEGCGG	IFASIDS	KSDIEFLVGNAG	TAMRPLTA	AAVTAAGN	ASVYLDGVP	PRMRERPIODLV
100	RIILLAAAL	SEGTTVVDNLLN	SDINMYLMDAL	KRLGNVETD	SENPAVVEGCGG	IFASIDS	KSDIEFLVGNAG	TAMRPLTA	AAVTAAGN	ASVYLDGVP	PRMRERPIODLV
100	RIILLAAAL	SEGTTVVDNLLN	SDINMYLMDAL	KRLGNVETD	SENPAVVEGCGG	IFASIDS	KSDIEFLVGNAG	TAMRPLTA	AAVTAAGN	ASVYLDGVP	PRMRERPIODLV
29	RIILLAAAL	SEGTTVVDNLLN	SDINMYLMDAL	KRLGNVETD	SENPAVVEGCGG	IFASIDS	KSDIEFLVGNAG	TAMRPLTA	AAVTAAGN	ASVYLDGVP	PRMRERPIODLV
											atepsps. PRO
214	VGLKQAGAD	VEGLTGNCP	PPVRVANGGL	PGGKVL	SGSIS	SOYLTA	LMSAPLAL	GDVEIEIVDK	LISVPYVENT	KLME	REGVSVEHSDS
210	VGLKQAGAD	VEGLTGNCP	PPVRVANGGL	PGGKVL	SGSIS	SOYLTA	LMSAPLAL	GDVEIEIVDK	LISVPYVENT	KLME	REGVSVEHSDS
210	DGLKQAGAE	VDCLGKOP	PPRIVSKGGL	PGGKVL	SGSIS	SOYLTA	LMSAPLAL	GDVEIEIVDK	LISVPYVENT	KLME	REGVSVEHSDS
138	VGLKQAGAD	VEGLTGNCP	PPVRVANGGL	PGGKVL	SGSIS	SOYLTA	LMSAPLAL	GDVEIEIVDK	LISVPYVENT	KLME	REGVSVEHSDS
											atepsps. PRO
324	YVEGDASSA	CYFLAGAA	ITGETVTV	VEGCGTTS	LOGDNK	FAEVL	EKGCKV	SVWTENS	SVTVGPP	PRDAFGMRHL	RAIDVNNKMP
320	YVEGDASSA	CYFLAGAA	ITGETVTV	VEGCGTTS	LOGDNK	FAEVL	EKGCKV	SVWTENS	SVTVGPP	PRDAFGMRHL	RAIDVNNKMP
320	FVEGDASSA	CYFLAGAA	AVTGGTIT	VEGCGTNS	LOGDNK	FAEVL	EKGCKV	SVWTENS	SVTVGPP	PRDAFGMRHL	RAIDVNNKMP
248	YVEGDASSA	CYFLAGAA	ITGETVTV	VEGCGTTS	LOGDNK	FAEVL	EKGCKV	SVWTENS	SVTVGPP	PRDAFGMRHL	RAIDVNNKMP
											atepsps. PRO
434	KETERMIA	ICTELRKL	GATVEGSDY	CVITPPK	KVKTA	AEIDTVDD	HRMAMAF	SLAACAD	VPVITIND	SGCTRKT	FPDPYFQVLE
430	KETERMIA	ICTELRKL	GATVEGSDY	CVITPPK	KVKTA	AEIDTVDD	HRMAMAF	SLAACAD	VPVITIND	SGCTRKT	FPDPYFQVLE
430	KETERMIA	ICTELRKL	GATVEGSDY	CVITPPK	KVKTA	AEIDTVDD	HRMAMAF	SLAACAD	VPVITIND	SGCTRKT	FPDPYFQVLE
358	KETERMIA	ICTELRKL	GATVEGSDY	CVITPPK	KVKTA	AEIDTVDD	HRMAMAF	SLAACAD	VPVITIND	SGCTRKT	FPDPYFQVLE
											atepsps. PRO
											bneppsps. PRO
											petaraoa. PRO
											zmeppsps. PRO

FIG. 4

Oligo Name Oligo Sequence (5'→3')

ATEPS-A₁₇₇

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTGCTGCATTACCGAG

ATEPS-AI

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTATTGCTGCATTACCGAG

ATEPS-IS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTATTCTGCATTACCGAG

ATEPS-AS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTGTTGCTGCATTACCGAG

ATEPS-AIS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTATTGCTGCATTACCGAG

ATEPS-I₁₇₇

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTATTGCATTACCGAG

ATEPS-VS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTACTCTGCATTACCGAG

ATEPS-LS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTAATCTGCATTACCGAG

ATEPS-AV

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTACTGCTGCATTACCGAG

ATEPS-AL

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTAATGCTGCATTACCGAG

FIG. 5




FIG. 6

Arabisdonosis clones

Bacillus AS WT Salmonella

L E L E L E L E




FIG. 7

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on *(if applicable)*
☐ was filed in the United States on as Application No. *(for declaration not accompanying application)*
 with amendment(s) filed on *(if applicable)*
☐ was filed as PCT international Application No. on and was amended under PCT Article 19 on *(if applicable)*

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/158,027	October 7, 1999
60/173,564	December 30, 1999

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY. As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stumpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:		PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N Y 10036-2711		DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS LLP DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME BEETHAM	FIRST NAME PETER	MIDDLE NAME R.	
	RESIDENCE & CITIZENSHIP	CITY CARLSBARD	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP AUSTRALIA	
	POST OFFICE ADDRESS	STREET 7128 TANAGER DRIVE	CITY CARLSBAD	STATE OR COUNTRY CALIFORNIA	ZIP CODE 92009
202	FULL NAME OF INVENTOR	LAST NAME AVISSAR	FIRST NAME PATRICIA	MIDDLE NAME L.	
	RESIDENCE & CITIZENSHIP	CITY EAST BRUNSWICK	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 32 REVOCK ROAD	CITY EAST BRUNSWICK	STATE OR COUNTRY NEW JERSEY	ZIP CODE 08816
203	FULL NAME OF INVENTOR	LAST NAME WALKER	FIRST NAME KEITH	MIDDLE NAME A.	
	RESIDENCE & CITIZENSHIP	CITY SAN DIEGO	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 13315 ROXTON CIRCLE	CITY SAN DIEGO	STATE OR COUNTRY CALIFORNIA	ZIP CODE 92130
204	FULL NAME OF INVENTOR	LAST NAME METZ	FIRST NAME RICHARD	MIDDLE NAME A.	
	RESIDENCE & CITIZENSHIP	CITY LAWRENCEVILLE	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 37 WINTHROP ROAD	CITY LAWRENCEVILLE	STATE OR COUNTRY NEW JERSEY	ZIP CODE 08648

I HEREBY DECLARE THAT ALL STATEMENTS MADE HEREIN OF MY OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENTS MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILLFUL FALSE STATEMENTS AND THE LIKE SO MADE ARE PUNISHABLE BY FINE OR IMPRISONMENT, OR BOTH, UNDER SECTION 1001 OF TITLE 18 OF THE UNITED STATES CODE AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE APPLICATION OR ANY PATENT ISSUING THEREON

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
PETER R. BEETHAM	PATRICIA L. AVISSAR	KEITH A. WALKER
DATE	DATE	DATE
SIGNATURE OF INVENTOR 204		
RICHARD A. METZ		
DATE		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Beetham et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: On even date herewith

Examiner: To be assigned

For: NON-TRANSGENIC HERBICIDE
RESISTANT PLANTS

Attorney Docket No.: 7991-086

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: October 10, 2000

By H. E. Friebe
REG NO 40,203
Thomas E. Friebe 29,258
Thomas E. Friebe (Reg.No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

SEQUENCE LISTING

<110> Beetham, P.
Avissar, P.
Walker, K.
Metz, R.

<120> NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

<130> 7991-086

<150> 60/158,027

<151> 1999-10-07

<150> 60/173,564

<151> 1999-12-30

<160> 44

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2763

<212> DNA

<213> Arabidopsis thaliana

<400> 1

cccttcacgt	ctttttaga	aacccacatta	tctttcttag	ggcccaattg	aaaacccaca	60
ttttctttca	cctaaccac	caaagccttg	cacatgttga	cgtgaacacc	aaactaacac	120
gtgtcact	gccagtgggt	atgataaatg	ctcataccat	accagagtca	tagagttttt	180
ggttggtgaa	agatttgacg	gatgccttct	tctcatttct	caccaactcc	ctccaaaccc	240
aacaaaatgt	ttatattagc	aaagccgcca	aagtgtaaac	gaaagtatat	aaatttcatt	300
tctgtgatct	tacgtaattg	gaggaagatc	aaaattttca	atccccattc	ttcgattgct	360
tcaattgaag	tttctccgat	ggcgcaagtt	agcagaatct	gcaatgggtg	gcagaaccca	420
tctcttatct	ccaatctctc	gaaatccagt	caacgcaaat	ctcccttata	ggtttctctg	480
aagacgcagc	agcatccacg	agcttatccg	atttcgtcgt	cgtggggatt	gaagaagagt	540
gggatgacgt	taattggctc	tgagcttcgt	cctcttaagg	tcattgtctc	tgtttccacg	600
gcggagaaa	cgtcggagat	tgtacttcaa	cccattagag	aaatctccgg	tcttattaag	660
cttcctgggt	ccaagtctct	atcaaatcgg	atcctgcttc	tcgtgctctc	gtctgaggta	720
tatatcactt	cgtttcgtcc	ttctctgtaa	tctgaactta	gattataaag	attgataactt	780
taccattttg	ctgtgggttt	atagggaaca	actgtagtgg	acaacttggt	gaatagcgat	840
gacatcaatt	acatgcttga	tgcgttgaag	agattgggac	ttaatgtgga	aactgacagt	900
gaaaataatc	gtgctgtagt	tgaaggatgt	ggcgggatat	tcccagcttc	catagattca	960
aagagtgata	tcgaaacttta	cctcggtaat	gcaggaacag	caatgcgtcc	acttaccgct	1020
gcggtcactg	ctgcaggtgg	aaacgcaagg	tagattgaag	gagttgatgc	ttcttggtat	1080
ttgatgttta	aggaatggag	cttttggtga	tgctttatga	tccatttatt	ccagttatgt	1140
gcttgatggg	gtgcctcgta	tgagagaaa	acctataggg	gatttggttg	ttggtcttaa	1200
gcagcttggt	gctgatgttg	aatgtactct	tggaactaac	tgccctcctg	ttcgtgtcaa	1260
cgctaattgg	ggccttcccg	gtggaaaagg	tagatcttgc	aaatggcatg	tgaatatgta	1320
atctcgttcc	ttactctatg	aacacttgca	gaaatgtgtg	ttcatcatag	ccttagcttg	1380
acaagatttc	agttttta	ctactctcaa	cggatggatc	ctaaaataga	atcggatttg	1440
gtgattgggt	ttcgttctcg	attaccgttt	tcgttgtagt	atttcttgat	taacaattag	1500
gagacatgtt	atgcatttgc	aggtgaagct	ttctggatca	attagtagtc	agtacttgac	1560
tgctctgctc	atgtctgctc	ccttagctct	tggagacgtc	gagattgaga	ttgtcgataa	1620
attaatttct	gttccatag	ttgaaatgac	attgaagttg	atggaacgtt	tcggggttag	1680
tgctgagcat	agtgatagct	gggatcggtt	ctttgtcaag	ggcgggcaaa	aatacaagta	1740
ggagttattc	ttttcttcct	tttctgaaat	cacatccctt	agcttgacaa	tataatgact	1800

```

aaaagggtgaa tgattcaggt ctccgggtaa tgcgtatgta gaagggtgatg cttctagtgc 1860
atgttatttc ttggctgggtg ctgccattac cggtgaaact gtcacagtcg aagggttggtg 1920
aactaccagc ttgcaggtaa tatttgatca ctgaatcatc gacgaggctg ttaagtttat 1980
agtgaatttc gtctaggtca aagtttcatc ttttgacaag ttgtatataa catattcgca 2040
agattctaag ctcaattttt gtgatgaatc tctagggaga tgtaaaattc gccgaggtcc 2100
ttgagaaaat gggatgtaaa gtgtcctgga cagagaacag tgtgactgtg acaggaccac 2160
ctagagatgc ttttggaatg agacacttgc gggctattga tgtcaacatg aacaaaatgc 2220
ctgatgtagc catgaccctt gccgtcggtg ctctctttgc tgacgggtcca accaccatta 2280
gagatggtaa gtaaaaagct ctctcttata attaagggtt ctcaatattc atgatcactt 2340
aattctgttt gggttaatata gtggctagct ggagagtaaa ggagacagaa aggatgattg 2400
ccatttgcac agagcttaga aaagtaagag attcttatct ctctctttct gtctcttgac 2460
agtgtcatt ctaagtaatt agctcataaa tttgtgtgtt tgtgttcagc tgggagctac 2520
agtgaagaa ggttcagatt attgtgtgat aactccgcc aaaaagggtga aaacggcaga 2580
gattgataca tatgatgatc atagaatggc aatggcattc tctcttgag cttgtgctga 2640
tgttccaatc accatcaacg actctggttg caccaggaaa accttccccg actacttcca 2700
agtacttgaa agaatcacia agcactaaac aataaactct gttttttctt ctgatccaag 2760
ctt

```

<210> 2

<211> 520

<212> PRT

<213> Arabidopsis thaliana

<400> 2

```

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu
 1          5          10          15
Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val
 20          25          30
Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser
 35          40          45
Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg
 50          55          60
Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Glu Lys Ala Ser Glu
 65          70          75          80
Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu Ile Lys Leu Pro
 85          90          95
Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser
100          105          110
Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn Ser Asp Asp Ile Asn
115          120          125
Tyr Met Leu Asp Ala Leu Lys Arg Leu Gly Leu Asn Val Glu Thr Asp
130          135          140
Ser Glu Asn Asn Arg Ala Val Val Glu Gly Cys Gly Gly Ile Phe Pro
145          150          155          160
Ala Ser Ile Asp Ser Lys Ser Asp Ile Glu Leu Tyr Leu Gly Asn Ala
165          170          175
Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr Ala Ala Gly Gly
180          185          190
Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro
195          200          205
Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly Ala Asp Val Glu
210          215          220
Cys Thr Leu Gly Thr Asn Cys Pro Pro Val Arg Val Asn Ala Asn Gly
225          230          235          240
Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln
245          250          255
Tyr Leu Thr Ala Leu Leu Met Ser Ala Pro Leu Ala Leu Gly Asp Val
260          265          270

```


Glu Ile Glu Ile Val Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met
 275 280 285
 Thr Leu Lys Leu Met Glu Arg Phe Gly Val Ser Val Glu His Ser Asp
 290 295 300
 Ser Trp Asp Arg Phe Phe Val Lys Gly Gly Gln Lys Tyr Lys Ser Pro
 305 310 315 320
 Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Cys Tyr Phe Leu
 325 330 335
 Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly
 340 345 350
 Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys
 355 360 365
 Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly
 370 375 380
 Pro Pro Arg Asp Ala Phe Gly Met Arg His Leu Arg Ala Ile Asp Val
 385 390 395 400
 Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala
 405 410 415
 Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg
 420 425 430
 Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys
 435 440 445
 Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro
 450 455 460
 Pro Lys Lys Val Lys Thr Ala Glu Ile Asp Thr Tyr Asp Asp His Arg
 465 470 475 480
 Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Ile Thr
 485 490 495
 Ile Asn Asp Ser Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln
 500 505 510
 Val Leu Glu Arg Ile Thr Lys His
 515 520

<210> 3
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 3

ctc ggt aat gca gca aca gca atg cgt cca ctt
 Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
 1 5 10

33

<210> 4
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 4

Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
 1 5 10

<210> 5

<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 5
ctc ggt aat gca gga ata gca atg cgt cca ctt
Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
1 5 10

33

<210> 6
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 6
Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
1 5 10

<210> 7
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 7
ctc ggt aat gca gca ata gca atg cgt cca ctt
Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
1 5 10

33

<210> 8
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 8
Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
1 5 10

<210> 9
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 9

ctc ggt aat gca gga ata gca atg cgt tca ctt
 Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
 1 5 10

33

<210> 10
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 10
 Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
 1 5 10

<210> 11
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 11
 ctc ggt aat gca gca aca gca atg cgt tca ctt
 Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
 1 5 10

33

<210> 12
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 12
 Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
 1 5 10

<210> 13
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 13
 ctc ggt aat gca gca ata gca atg cgt tca ctt
 Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
 1 5 10

33

<210> 14
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 14
 Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
 1 5 10

<210> 15
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 15
 ctc ggt aat gca gga gta gca atg cgt tca ctt
 Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
 1 5 10

33

<210> 16
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 16
 Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
 1 5 10

<210> 17
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 17
 ctc ggt aat gca gga tta gca atg cgt tca ctt
 Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
 1 5 10

33

<210> 18
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 18
 Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
 1 5 10

<210> 19
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>

```

<221> CDS
<222> (1)...(33)

<400> 19
ctc ggt aat gca gca gta gca atg cgt cca ctt
Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
1 5 10 33

<210> 20
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 20
Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
1 5 10

<210> 21
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 21
ctc ggt aat gca gca tta gca atg cgt cca ctt
Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
1 5 10 33

<210> 22
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 22
Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
1 5 10

<210> 23
<211> 3831
<212> DNA
<213> Brassisca napus

<220>
<221> modified_base
<222> 1...3831
<223> n=a, c, g, or t

<400> 23
agatcttataa ggctcttttc cagtctcacc taccaaaact ataagaaaat ccacttgctg 60
tctgaaatag cgcagctgga taaagtactt aagacgtggc acattattat tggctactag 120
aaaaaaaaact catacaccat cgtaggagtt gggggttggtg aagaatttga tgggtgcctc 180
tcccccccc actcacaaa ctcattgttct ttgtaaagcc gtcactacaa caacaaagga 240
gacgacagtt ctatagaaaa gctttcaaat tcaatcaatg gcgcaatcta gcagaatctg 300

```

ccatggcgctg	cagaacccat	gtgttatcat	ctccaatctc	tccaaatacca	acaaaaacaa	360
atcacctttc	tccgtctcct	tgaagacgca	tcagcctcga	gcttcttcgt	ggggattgaa	420
gaagagtggg	acgatgctaa	acggttctgt	aattcgcccg	gttaaggtaa	cagcttctgt	480
ttccacgtcc	gagaaagctt	cagagattgt	gcttcaacca	atcagagaaa	tctcgggtct	540
cattaagcta	cccggatcca	aatctctctc	caatcggatc	ctccttcttg	ccgctctatc	600
tgaggtagat	atacttgctt	agtgttaggc	ctttgctgtg	agattttggg	aactatagac	660
aattttagtaa	gaattttatat	ataatttttt	taaaaaaaat	cagaagccta	tatatattta	720
aattttttcca	aaattttttgg	aggttatagg	cttatgttac	accatttctag	tctgcatctt	780
tcggttttgag	actgaagaat	tttatttttt	aaaaaattat	tatagggaac	tactgtagtg	840
gacaacttgt	tgaacagtga	tgacatcaac	tacatgcttg	atgcgttgaa	gaagctgggg	900
cttaacgtgg	aacgtgacag	tgtaaacac	cgtgcggttg	ttgaaggatg	cgggtggaata	960
ttcccagctt	ccttagattc	caagagtgat	attgagttgt	accttgggaa	tgaggaaca	1020
gccatgcgtc	cactcacccg	tgacagttaca	gctgcaggtg	gcaacgcgag	gtaagggttaa	1080
cgagtttttt	gttattgtca	agaaattgat	cttgtgtttg	atgcttttag	tttgggttgt	1140
tttctagtta	tgtacttgat	ggggtgccta	gaatgagggg	aagacctata	ggagatttgg	1200
ttgttggtct	taagcagctt	ggtgctgatg	ttgagtgtac	tcttggcact	aactgtcctc	1260
ctgttcgtgt	caatgctaata	ggtggccttc	ccggtggaaa	ggtgatcttc	acatttactc	1320
tatgaattgt	ttgcagcagt	ctttgttcat	cacagccttt	gcttcacatt	atttcatctt	1380
ttagtttgtt	gttatattac	ttgatggatc	tttaaaaagg	aattgggtct	ggtgtgaaag	1440
tgattagcaa	tctttctcga	ttccttgacg	ggcgtggggc	attactaagt	gaaacattag	1500
cctattaacc	cccaaaat	ttgaaaaaaa	tttagtatat	ggccccaaaa	tagtttttta	1560
aaaaattaga	aaaactttta	ataaatcgtc	tacagtcccn	naaatcttag	agccggccct	1620
gcttgatagg	tttctcgatt	gatataattag	actatgtttt	gaattttcag	gtgaagcttt	1680
ctggatcgat	cagtagtcag	tacttgactg	ccctcctcat	ggcagctcct	ttagctcttg	1740
gagacgtgga	gattgagatc	attgataaac	tgatatctgt	tccatatgtt	gaaatgacat	1800
tgaagtgat	ggagcgtttt	ggtgttagtg	ccgagcatag	tgatagctgg	gatcgtttct	1860
ttgtcaaggg	cggtcagaaa	tacaagtaat	gagttctttt	aagttgagag	ttagattgaa	1920
gaatgaatga	ctgattaacc	aaatggcaaa	actgattcag	gtcgccctggt	aatgcttatg	1980
tagaagggtga	tgcttctagt	gctagctatt	tcttggctgg	tgctgccatt	actggtgaaa	2040
ctgttactgt	cgaagggtgt	ggaacaacta	gcctccagg	agtttatcca	ctctgaatca	2100
tcaaatatta	ttctccctcc	gttttatggt	aagtgtcatt	agcttttaaa	ttttgtttca	2160
ttaaaagtgt	catttttacct	tttcaatgca	tatatataat	aaattttcca	gtttttacta	2220
attcattaat	tagcaaaaatc	aaacaaaaat	tatatataat	aatgtaaaat	tcgtaatttg	2280
tgtgcaaata	ccttaaacct	tatgaaacgg	aaaccttatg	aaacagaggg	agtactaatt	2340
ttataataaaa	atttgattag	ttcaaagttg	tgtataacat	gttttgtaag	aatctaagct	2400
cattctcttt	ttattttttg	tgatgaatcc	aaaggagat	gtgaaattcg	cagaggttct	2460
tgagaaaatg	ggatgtaaaag	tgatcatggac	agagaacagt	gtgactgtga	ctggaccatc	2520
aagagatgct	tttggaatga	ggcacttgcg	tgctgttgat	gtcaacatga	acaaaatgcc	2580
tgatgtagcc	atgactctag	cogttgttgc	tctctttgcc	gatgggtccaa	ccaccatcag	2640
agatggtataa	gcaaaaccct	ctctttgaat	cagcgtgttt	taaaagattc	atggttgctt	2700
aaactctatt	tggtcaatgt	agtggctagc	tggagagtta	aggagacaga	gaggatgatt	2760
gccatttgca	cagagcttag	aaaggtaagt	ttccttttct	ctcatgctct	ctcattcgaa	2820
gttaatcggt	gcataacttt	ttgcggtttt	tttttttgcg	ttcagcttgg	agctacagt	2880
gaagaagggt	cagattattg	tgtgataact	ccaccagcaa	aggtgaaacc	ggcggagatt	2940
gatacgtatg	atgatcatag	aatggcgatg	gcgttctcgc	ttgcagcttg	tgctgatgtt	3000
ccagtcacca	tcaaggatcc	tggctgcacc	aggaagactt	tccctgacta	cttccaagtc	3060
cttgaaaagta	tcacaaagca	ttaaaagacc	ctttcctctg	atccaaatgt	gagaatctgt	3120
tgctttctct	ttgttgccac	tgtaacattt	attagaagaa	caaagtgtgt	gtgttaagag	3180
tgtgtttgct	tgtaatgaac	tgagttagat	gcaatogttg	aatcagtttt	gggccttaat	3240
aaagggttta	ggaagctgca	gcgagatgat	tgtttttgat	cgatcatctt	tgaaaatgtg	3300
tttgtttgag	taatttttct	agggttgagt	tgattacact	aagaaacact	ttttgatttt	3360
ctattacacc	tatagacact	tcttacatgt	gacacacttt	gttgttggca	agcaacagat	3420
tgtggacaat	tttgccctta	atggaaagaa	cacagttgtg	gatgggtgat	ttgtggacga	3480
ttccatgtgt	ggtaggggtg	atttgtggac	ggatgatgtg	tagatgagtg	atgagtaatg	3540
tgtgaatatg	tgatgttaat	gtgtttatag	tagataagtg	gacaaaactc	ctgttttgat	3600
tccataaaaac	tatacaacaa	tacgtggaca	tggactcatg	ttactaaaat	tataccgtaa	3660
aacgtggaca	cggactctgt	atctccaata	caaacacttg	gcttcttcag	ctcaattgat	3720
aaattatctg	cagttaaaact	tcaatcaaga	tgagaaaagag	atgatattgt	gaatatgagc	3780

ggagagagaa atcgaagaag cgtttacctt ttgtcggaga gtaatagatc t

3831

<210> 24

<211> 1944

<212> DNA

<213> Petunia hybrida

<400> 24

gaattccctc	aatctttact	ttcaagaatg	gcacaaatta	acaacatggc	tcaagggata	60
caaaccctta	atcccaattc	caatttccat	aaaccccaag	ttcctaaatc	ttcaagtttt	120
cttgtttttg	gatctaaaaa	actgaaaaat	tcagcaaatt	ctatgttggg	tttgaaaaaa	180
gattcaattt	ttatgcaaaa	gttttgttcc	tttaggattt	cagcatcagt	ggctacagca	240
cagaagcctt	ctgagatagt	gttgcaaccc	attaaagaga	tttcaggcac	tggttaaattg	300
cctggctcta	aatcattatc	taatagaatt	ctccttcttg	ctgccttata	tgaaggaaca	360
actgtggttg	acaatttact	aagtagtgat	gatattcatt	acatgcttgg	tgcccttga	420
acacttgga	tgcatgtaga	agaagatagt	gcaaaccaac	gagctgttgt	tgaaggttgt	480
ggtgggcttt	tccctgttgg	taaagagtcc	aaggaagaaa	ttcaactgtt	ccttggaaat	540
gcaggaacag	caatgcgggc	actaacagca	gcagttactg	tagctgggtg	aaattcaagg	600
tatgtacttg	atggagttcc	tcgaatgaga	gagagaccaa	ttagtgattt	ggttgatggg	660
cttaaacagc	ttggtgcaga	ggttgattgt	ttccttggtg	cgaaatgtcc	tcctgttcga	720
attgtcagca	agggaggtct	tcctggaggg	aagggtcaagc	tctctggatc	cattagcagc	780
caataactga	ctgctctgct	tatggctgct	ccactggctt	taggagatgt	ggagattgaa	840
atcattgaca	aactaattag	tgtaccttat	gtcgagatga	cattgaagtt	gatggagcga	900
tttggatatt	ctgtggagca	cagtagtagc	tgggacaggt	tctttgtccg	aggaggtcag	960
aaatacaagt	ctcctggaaa	agcttttgtc	gaagggtgat	cttcaagtgc	tagctacttc	1020
ttggctggtg	cagcagtcac	aggtggaact	atcactgttg	aagggttgtg	gacaaacagt	1080
ttacaggggg	atgtcaaaat	tgctgaggta	cttgaaaaaa	tgggagctga	agttacgtgg	1140
acagagaaca	gtgtcacagt	caaaggacct	ccaaggagtt	cttctgggag	gaagcatttg	1200
cgtgccattg	atgtgaacat	gaataaaatg	cctgatgttg	ccatgacact	tgctgttgtt	1260
gcactttatg	ctgatggctc	cacagctata	agagatgttg	ctagctggag	agtcaaggaa	1320
actgagcgca	tgatcgccat	atgcacagaa	cttaggaagt	taggagcaac	cgttgaagaa	1380
ggaccagact	actgcataat	cacccacccg	gagaaactaa	atgtgaccga	tattgatata	1440
tacgatgatc	acaggatggc	catggctttt	tctcttgctg	cttgtgcaga	tggtcccgtc	1500
accatcaatg	accctggctg	cacgcggaaa	accttcctta	actactttga	tgtacttcag	1560
cagtactcca	agcattgaac	cgcttcccta	tattgcagaa	tgtaagtaag	aatatgtgaa	1620
gagtttagtt	cttgtacaag	acaggctacg	actgcctggg	atcagaacca	caatgggttc	1680
catttcagtt	cagaagggca	ttccaaggct	tcgaactctt	tacttatttg	cgagtgatga	1740
aatgtatttg	ttagagttga	gcttcttttt	gtcttttaag	aatgtacact	aatagagtta	1800
agaattacta	gtatgggcca	gtgtaaggag	tactattact	ctttgcttat	tttattgatt	1860
gagttttgtc	aaggatctgg	ctttgtcaag	aattactggg	taattttatt	gacaatctca	1920
tgtgtctaaa	tgaaattggt	tgat				1944

<210> 25

<211> 1335

<212> DNA

<213> Zea mays

<400> 25

gcggggtccg	aggagatcgt	gctgcagccc	atcaaggaga	tctccggcac	cgtcaagctg	60
ccgggggtcca	agtcgctttc	caaccgggac	ctcctactcg	ccgccctgtc	cgaggggaca	120
acagtgggtg	ataacctgct	gaacagtgag	gatgtccact	acatgctcgg	ggccttgagg	180
actcttggtc	tctctgtcga	agcggacaaa	gctgccaaaa	gagctgtagt	tggtggctgt	240
ggtggaaagt	tcccagttga	ggatgctaaa	gaggaagtgc	agctcttctt	ggggaatgct	300
ggaactgcaa	tgcggccatt	gacagcagct	gttactgctg	ctgggtggaa	tgcaacttac	360
gtgcttgatg	gagtaccaag	aatgagggag	agacccattg	gcgacttggg	tgctcgattg	420
aagcagcttg	gtgcagatgt	tgattgtttc	cttggcactg	actgcccacc	tggtcgtgtc	480
aatggaatcg	gagggtacc	tggtggcaag	gtcaagctgt	ctggctccat	cagcagtcag	540
tacttgagtg	ccttgctgat	ggctgctcct	ttggctcttg	gggatgtgga	gattgaaatc	600

attgataaat	taatctccat	tccgtacgtc	gaaatgacat	tgagattgat	ggagcgtttt	660
ggtgtgaaag	cagagcattc	tgatagctgg	gacagattct	acattaaggg	aggtcaaaaa	720
tacaagtccc	ctaaaaatgc	ctatgttgaa	ggtgatgcct	caagcgcaag	ctattttcttg	780
gctgggtgctg	caattactgg	agggactgtg	actgtggaag	gttgtggcac	caccagtttg	840
caggggtgatg	tgaagtttgc	tgaggtactg	gagatgatgg	gagcgaaggt	tacatggacc	900
gagactagcg	taactgttac	tggcccaccg	cgggagccat	ttgggaggaa	acacctcaag	960
gcgattgatg	tcaacatgaa	caagatgcct	gatgtcgcca	tgactcttgc	tgtgggtgcc	1020
ctctttgccc	atggcccgcac	agccatcaga	gacgtggcct	cctggagagt	aaaggagacc	1080
gagaggatgg	ttgcgatccg	gacggagcta	accaagctgg	gagcatctgt	tgaggaaggg	1140
ccggactact	gcatactcac	gccgccggag	aagctgaacg	tgacggcgat	cgacacgtac	1200
gacgaccaca	ggatggccat	ggccttctcc	cttgccgcct	gtgccgaggt	ccccgtcacc	1260
atccgggacc	ctgggtgcac	ccggaagacc	ttccccgact	acttcgatgt	gctgagcact	1320
ttcgtcaaga	attaa					1335

<210> 26

<211> 516

<212> PRT

<213> Brassisca napus

<400> 26

Met	Ala	Gln	Ser	Ser	Arg	Ile	Cys	His	Gly	Val	Gln	Asn	Pro	Cys	Val
1				5					10					15	
Ile	Ile	Ser	Asn	Leu	Ser	Lys	Ser	Asn	Gln	Asn	Lys	Ser	Pro	Phe	Ser
			20					25					30		
Val	Ser	Leu	Lys	Thr	His	Gln	Pro	Arg	Ala	Ser	Ser	Trp	Gly	Leu	Lys
		35					40					45			
Lys	Ser	Gly	Thr	Met	Leu	Asn	Gly	Ser	Val	Ile	Arg	Pro	Val	Lys	Val
	50					55					60				
Thr	Ala	Ser	Val	Ser	Thr	Ser	Glu	Lys	Ala	Ser	Glu	Ile	Val	Leu	Gln
65					70					75					80
Pro	Ile	Arg	Glu	Ile	Ser	Gly	Leu	Ile	Lys	Leu	Pro	Gly	Ser	Lys	Ser
				85					90					95	
Leu	Ser	Asn	Arg	Ile	Leu	Leu	Leu	Ala	Ala	Leu	Ser	Glu	Gly	Thr	Thr
			100					105					110		
Val	Val	Asp	Asn	Leu	Leu	Asn	Ser	Asp	Asp	Ile	Asn	Tyr	Met	Leu	Asp
		115					120					125			
Ala	Leu	Lys	Lys	Leu	Gly	Leu	Asn	Val	Glu	Arg	Asp	Ser	Val	Asn	Asn
		130				135					140				
Arg	Ala	Val	Val	Glu	Gly	Cys	Gly	Gly	Ile	Phe	Pro	Ala	Ser	Leu	Asp
145					150					155					160
Ser	Lys	Ser	Asp	Ile	Glu	Leu	Tyr	Leu	Gly	Asn	Ala	Gly	Thr	Ala	Met
				165					170					175	
Arg	Pro	Leu	Thr	Ala	Ala	Val	Thr	Ala	Ala	Gly	Gly	Asn	Ala	Ser	Tyr
			180					185					190		
Val	Leu	Asp	Gly	Val	Pro	Arg	Met	Arg	Glu	Arg	Pro	Ile	Gly	Asp	Leu
		195					200					205			
Val	Val	Gly	Leu	Lys	Gln	Leu	Gly	Ala	Asp	Val	Glu	Cys	Thr	Leu	Gly
		210				215					220				
Thr	Asn	Cys	Pro	Pro	Val	Arg	Val	Asn	Ala	Asn	Gly	Gly	Leu	Pro	Gly
225					230					235					240
Gly	Lys	Val	Lys	Leu	Ser	Gly	Ser	Ile	Ser	Ser	Gln	Tyr	Leu	Thr	Ala
				245					250					255	
Leu	Leu	Met	Ala	Ala	Pro	Leu	Ala	Leu	Gly	Asp	Val	Glu	Ile	Glu	Ile
			260					265					270		
Ile	Asp	Lys	Leu	Ile	Ser	Val	Pro	Tyr	Val	Glu	Met	Thr	Leu	Lys	Leu
		275					280					285			
Met	Glu	Arg	Phe	Gly	Val	Ser	Ala	Glu	His	Ser	Asp	Ser	Trp	Asp	Arg
	290					295					300				

Phe	Phe	Val	Lys	Gly	Gly	Gln	Lys	Tyr	Lys	Ser	Pro	Gly	Asn	Ala	Tyr
305					310					315					320
Val	Glu	Gly	Asp	Ala	Ser	Ser	Ala	Ser	Tyr	Phe	Leu	Ala	Gly	Ala	Ala
				325					330					335	
Ile	Thr	Gly	Glu	Thr	Val	Thr	Val	Glu	Gly	Cys	Gly	Thr	Thr	Ser	Leu
			340					345					350		
Gln	Gly	Asp	Val	Lys	Phe	Ala	Glu	Val	Leu	Glu	Lys	Met	Gly	Cys	Lys
		355					360					365			
Val	Ser	Trp	Thr	Glu	Asn	Ser	Val	Thr	Val	Thr	Gly	Pro	Ser	Arg	Asp
	370					375					380				
Ala	Phe	Gly	Met	Arg	His	Leu	Arg	Ala	Val	Asp	Val	Asn	Met	Asn	Lys
385					390					395					400
Met	Pro	Asp	Val	Ala	Met	Thr	Leu	Ala	Val	Val	Ala	Leu	Phe	Ala	Asp
				405					410					415	
Gly	Pro	Thr	Thr	Ile	Arg	Asp	Val	Ala	Ser	Trp	Arg	Val	Lys	Glu	Thr
			420					425					430		
Glu	Arg	Met	Ile	Ala	Ile	Cys	Thr	Glu	Leu	Arg	Lys	Leu	Gly	Ala	Thr
		435					440					445			
Val	Glu	Gly	Gly	Ser	Asp	Tyr	Cys	Val	Ile	Thr	Pro	Pro	Ala	Lys	Val
	450					455					460				
Lys	Pro	Ala	Glu	Ile	Asp	Thr	Tyr	Asp	Asp	His	Arg	Met	Ala	Met	Ala
465					470					475					480
Phe	Ser	Leu	Ala	Ala	Cys	Ala	Asp	Val	Pro	Val	Thr	Ile	Lys	Asp	Pro
				485					490					495	
Gly	Cys	Thr	Arg	Lys	Thr	Phe	Pro	Asp	Tyr	Phe	Gln	Val	Leu	Glu	Ser
			500					505					510		
Ile	Thr	Lys	His												
		515													

<210> 27

<211> 516

<212> PRT

<213> Petunia hybrida

<400> 27

Met	Ala	Gln	Ile	Asn	Asn	Met	Ala	Gln	Gly	Ile	Gln	Thr	Leu	Asn	Pro
1				5					10					15	
Asn	Ser	Asn	Phe	His	Lys	Pro	Gln	Val	Pro	Lys	Ser	Ser	Ser	Phe	Leu
			20					25					30		
Val	Phe	Gly	Ser	Lys	Lys	Leu	Lys	Asn	Ser	Ala	Asn	Ser	Met	Leu	Val
		35					40					45			
Leu	Lys	Lys	Asp	Ser	Ile	Phe	Met	Gln	Lys	Phe	Cys	Ser	Phe	Arg	Ile
	50					55					60				
Ser	Ala	Ser	Val	Ala	Thr	Ala	Gln	Lys	Pro	Ser	Glu	Ile	Val	Leu	Gln
65					70					75					80
Pro	Ile	Lys	Glu	Ile	Ser	Gly	Thr	Val	Lys	Leu	Pro	Gly	Ser	Lys	Ser
				85					90					95	
Leu	Ser	Asn	Arg	Ile	Leu	Leu	Leu	Ala	Ala	Leu	Ser	Glu	Gly	Thr	Thr
		100						105					110		
Val	Val	Asp	Asn	Leu	Leu	Ser	Ser	Asp	Asp	Ile	His	Tyr	Met	Leu	Gly
		115					120					125			
Ala	Leu	Lys	Thr	Leu	Gly	Leu	His	Val	Glu	Glu	Asp	Ser	Ala	Asn	Gln
	130					135					140				
Arg	Ala	Val	Val	Glu	Gly	Cys	Gly	Gly	Leu	Phe	Pro	Val	Gly	Lys	Glu
145					150					155					160
Ser	Lys	Glu	Glu	Ile	Gln	Leu	Phe	Leu	Gly	Asn	Ala	Gly	Thr	Ala	Met
				165					170					175	

Ser	Glu	Asp	Val	His	Tyr	Met	Leu	Gly	Ala	Leu	Arg	Thr	Leu	Gly	Leu	50	55	60
Ser	Val	Glu	Ala	Asp	Lys	Ala	Ala	Lys	Arg	Ala	Val	Val	Val	Gly	Cys	65	70	75
Gly	Gly	Lys	Phe	Pro	Val	Glu	Asp	Ala	Lys	Glu	Glu	Val	Gln	Leu	Phe	85	90	95
Leu	Gly	Asn	Ala	Gly	Thr	Ala	Met	Arg	Pro	Leu	Thr	Ala	Ala	Val	Thr	100	105	110
Ala	Ala	Gly	Gly	Asn	Ala	Thr	Tyr	Val	Leu	Asp	Gly	Val	Pro	Arg	Met	115	120	125
Arg	Glu	Arg	Pro	Ile	Gly	Asp	Leu	Val	Val	Gly	Leu	Lys	Gln	Leu	Gly	130	135	140
Ala	Asp	Val	Asp	Cys	Phe	Leu	Gly	Thr	Asp	Cys	Pro	Pro	Val	Arg	Val	145	150	155
Asn	Gly	Ile	Gly	Gly	Leu	Pro	Gly	Gly	Lys	Val	Lys	Leu	Ser	Gly	Ser	165	170	175
Ile	Ser	Ser	Gln	Tyr	Leu	Ser	Ala	Leu	Leu	Met	Ala	Ala	Pro	Leu	Ala	180	185	190
Leu	Gly	Asp	Val	Glu	Ile	Glu	Ile	Asp	Lys	Leu	Ile	Ser	Ile	Pro		195	200	205
Tyr	Val	Glu	Met	Thr	Leu	Arg	Leu	Met	Glu	Arg	Phe	Gly	Val	Lys	Ala	210	215	220
Glu	His	Ser	Asp	Ser	Trp	Asp	Arg	Phe	Tyr	Ile	Lys	Gly	Gly	Gln	Lys	225	230	235
Tyr	Lys	Ser	Pro	Lys	Asn	Ala	Tyr	Val	Glu	Gly	Asp	Ala	Ser	Ser	Ala	245	250	255
Ser	Tyr	Phe	Leu	Ala	Gly	Ala	Ala	Ile	Thr	Gly	Gly	Thr	Val	Thr	Val	260	265	270
Glu	Gly	Cys	Gly	Thr	Thr	Ser	Leu	Gln	Gly	Asp	Val	Lys	Phe	Ala	Glu	275	280	285
Val	Leu	Glu	Met	Met	Gly	Ala	Lys	Val	Thr	Trp	Thr	Glu	Thr	Ser	Val	290	295	300
Thr	Val	Thr	Gly	Pro	Pro	Arg	Glu	Pro	Phe	Gly	Arg	Lys	His	Leu	Lys	305	310	315
Ala	Ile	Asp	Val	Asn	Met	Asn	Lys	Met	Pro	Asp	Val	Ala	Met	Thr	Leu	325	330	335
Ala	Val	Val	Ala	Leu	Phe	Ala	Asp	Gly	Pro	Thr	Ala	Ile	Arg	Asp	Val	340	345	350
Ala	Ser	Trp	Arg	Val	Lys	Glu	Thr	Glu	Arg	Met	Val	Ala	Ile	Arg	Thr	355	360	365
Glu	Leu	Thr	Lys	Leu	Gly	Ala	Ser	Val	Glu	Glu	Gly	Pro	Asp	Tyr	Cys	370	375	380
Ile	Ile	Thr	Pro	Pro	Glu	Lys	Leu	Asn	Val	Thr	Ala	Ile	Asp	Thr	Tyr	385	390	395
Asp	Asp	His	Arg	Met	Ala	Met	Ala	Phe	Ser	Leu	Ala	Ala	Cys	Ala	Glu	405	410	415
Val	Pro	Val	Thr	Ile	Arg	Asp	Pro	Gly	Cys	Thr	Arg	Lys	Thr	Phe	Pro	420	425	430
Asp	Tyr	Phe	Asp	Val	Leu	Ser	Thr	Phe	Val	Lys	Asn					435	440	

<210> 29

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant primer

<400> 29
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctgtt gctgcattac 60
 cgag 64

<210> 30
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 30
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctatt gctgcattac 60
 cgag 64

<210> 31
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 31
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctatt cctgcattac 60
 cgag 64

<210> 32
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 32
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctgtt gctgcattac 60
 cgag 64

<210> 33
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 33
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctatt gctgcattac 60
 cgag 64

<210> 34
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Mutant primer

<400> 34

cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctggt attgcattac 60
cgag 64

<210> 35

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant primer

<400> 35

cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctact cctgcattac 60
cgag 64

<210> 36

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant primer

<400> 36

cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctaata cctgcattac 60
cgag 64

<210> 37

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant primer

<400> 37

cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctact gctgcattac 60
cgag 64

<210> 38

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant primer

<400> 38

cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctaata gctgcattac 60
cgag 64

<210> 39

<211> 5

<212> PRT

<213> Petunia hybrida

<400> 39
 Leu Phe Leu Gly Asn
 1 5

<210> 40
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 40
 gctctagaga aagcgtcggg gattgtactt 30

<210> 41
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 41
 gcagatctga gctcttagtg ctttgtgatt ctttcaagta c 41

<210> 42
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 42
 gcgtctagaa aaacgagata aggtgcag 28

<210> 43
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 43
 gcggtcctc aggatttttt cgaaagctta tttaaagt 38

<210> 44
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 44
 gaaagcgtcg gagattgtac 20